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Abstract 
Chronic airway diseases including cystic fibrosis (CF), asthma and chronic obstructive 
pulmonary disease (COPD) are characterized by reduced mucociliary clearance (MCC) 
that leads to mucus-obstructed and chronically inflamed airways and structural changes 
of the lung. Mice with airway-specific overexpression of the β-subunit of the epithelial 
sodium channel (Scnn1b) exhibit airway surface dehydration, mucus hyperconcentration 
and impaired MCC and share pathogenic key features of CF and other muco-obstructive 
lung diseases. Therefore, the Scnn1b-transgenic (Tg) mouse is a useful model to study 
pathophysiological mechanisms of chronic airway diseases in vivo. In this study, we 
investigated the role of MCC as an important innate defense mechanism in the 
pathogenesis of allergic airway disease and also aimed to understand the role of T and B 
cells as key cells of the adaptive immunity in chronic airway diseases. 
We analyzed allergen clearance mechanisms in juvenile wild-type (WT) and Scnn1b-Tg 
mice and validated the role of impaired MCC on allergen-induced type 2 airway 
inflammation in a house dust mite allergen (HDM) exposure model. Further, we 
determined effects of impaired MCC and allergen-induced type 2 airway inflammation in 
adult mice. Finally, we investigated if pharmacological improvement of MCC could 
prevent allergen-induced type 2 airway inflammation. To investigate the role of T and B 
cells in the pathogenesis of chronic airway diseases in vivo, we crossed Scnn1b-Tg mice 
with recombination activating gene 1 (RAG1) deficient mice (Rag1-/-) that lack mature T 
and B cells and compared inflammatory cell counts in bronchoalveolar lavage (BAL), 
transcript levels of T helper (Th)1, Th2 and Th17 cytokines, airway mucus obstruction 
and structural lung damage in juvenile Scnn1b-Tg mice with Scnn1b-Tg/Rag1-/- mice, 
and their WT and Rag1-/- littermates. 
We found that reduced allergen clearance from the airways aggravated eosinophilic 
airway inflammation, secretion of type 2 signature cytokines, and airway 
hyperresponsiveness (AHR) in juvenile Scnn1b-Tg mice. Interestingly, the induction of 
allergen-induced type 2 airway inflammation in adult WT and Scnn1b-Tg mice was 
abrogated demonstrating an age-dependent susceptibility caused by a type 2 biased 
immunity during the neonatal/juvenile age. Pharmacological improvement of airway 
surface hydration reduced allergen-induced airway inflammation and AHR in Scnn1b-Tg 
mice. Lack of Rag1 had no effect on elevated levels of neutrophils and eosinophils in 
BAL from juvenile Scnn1b-Tg mice. We identified elevated transcript levels of the 
cytokine Interleukin (IL)-17A in juvenile Scnn1b-Tg mice that was reduced in Scnn1b-
Tg/Rag1-/- mice. Flow cytometry revealed γδ T, CD4+ T cells and type 3 innate lymphoid 
Abstract   
XIV   
cells (ILC3s) as major sources of IL-17A in lungs of Scnn1b-Tg mice. Increased IL-17A-
production did not affect mucus plugging but might be associated with structural lung 
damage in juvenile Scnn1b-Tg mice. 
In summary, our data support that impaired clearance of inhaled allergens plays an 
important role in the pathogenesis of type 2 airway inflammation and suggest that 
therapeutic improvement of MCC may be an effective strategy to prevent disease-
aggravating inflammatory responses in patients with allergic asthma and other chronic 
airway diseases associated with mucociliary dysfunction including CF and COPD. 
Further, results from our study provide first insights into T and B cell-dependent 
mechanisms that might contribute to pathophysiological features of CF lung disease.  
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Zusammenfassung 
Chronische Atemwegserkrankungen wie zystische Fibrose (CF), Asthma und chronisch 
obstruktive Lungenerkrankung (COPD) zeichnen sich durch eine reduzierte mukoziliäre 
Clearance aus, die zu Mukus obstruierten und chronisch entzündeten Atemwegen mit 
strukturellen Veränderungen der Lunge führt. Mäuse mit Atemwegs-spezifischer 
Überexpression der β-Untereinheit des epithelialen Natriumkanals (Scnn1b) weisen eine 
Atemwegsdehydratation, eine Mukus-Hyperkonzentration und eine beeinträchtigte 
mukoziliäre Clearance auf. Des Weiteren zeigen sie pathogene Hauptmerkmale von CF 
und anderen Mukus obstruierten Atemwegserkrankungen. Daher ist die Scnn1b-
transgene (Tg) Maus ein geeignetes Modell, um pathophysiologische Mechanismen von 
chronischen Atemwegserkrankungen in vivo zu untersuchen. In dieser Studie 
untersuchten wir die Rolle von mukoziliärer Clearance als ein wichtiger angeborener 
Abwehrmechanismus bei der Pathogenese allergischer Atemwegserkrankungen, sowie 
die Rolle von T und B Zellen als Schlüsselzellen der adaptiven Immunantwort bei 
chronischen Atemwegserkrankungen. 
Wir analysierten Mechanismen der Allergen-Clearance bei juvenilen Wildtyp (WT) und 
Scnn1b-Tg-Mäusen und validierten die Rolle von beeinträchtigter mukoziliärer Clearance 
bei Allergen-induzierter Typ 2 Atemwegsentzündung in einem Hausstaubmilbenallergen 
Expositionsmodell. Ferner haben wir die Auswirkungen von beeinträchtigter mukoziliärer 
Clearance und Allergen-induzierter Atemwegsentzündung des Typs 2 bei adulten 
Mäusen bestimmt. Schließlich untersuchten wir, ob die pharmakologische Verbesserung 
der mukoziliären Clearance die Allergen-induzierte Atemwegsentzündung des Typs 2 
verhindern kann. Um die Rolle von T und B Zellen bei der Pathogenese von chronischen 
Atemwegserkrankungen in vivo zu untersuchen, kreuzten wir Scnn1b-Tg Mäuse mit 
Rag1-defizienten (Rag1-/-) Mäusen, welchen reife T und B Zellen fehlen. Wir verglichen 
die Anzahl der Entzündungszellen in der bronchoalveolären Lavage, Genexpression von 
T-Helfer 1, 2 und 17 Zytokinen, Mukusobstruktion und strukturelle Lungenschäden bei 
juvenilen Scnn1b-Tg Mäusen mit denen von Scnn1b-Tg/Rag1-/- Mäusen, ihren WT sowie 
Rag1-/- Kontrollen. 
Eine reduzierte Clearance von Allergenen aus den Atemwegen in juvenilen Scnn1b-Tg 
Mäusen verschlimmerte die eosinophile Atemwegsentzündung, die Sekretion von Typ 2 
Signaturzytokinen und die Atemwegshyperreaktivität. Interessanterweise wurde bei 
adulten WT und Scnn1b-Tg Mäusen die Induktion einer Allergen-induzierten Typ 2 
Atemwegsentzündung nicht beobachtet. Diese altersabhängige Anfälligkeit, eine 
Allergen-induzierte Type 2 Atemwegsentzündung zu entwickeln, wurde durch eine Typ 2 
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polarisierte Immunität während des neonatalen/juvenilen Alters verursacht. Die 
pharmakologische Verbesserung der Atemwegshydratation reduzierte die Allergen-
induzierte Atemwegsentzündung und -hyperreaktivität in Scnn1b-Tg Mäusen. Das 
Fehlen von Rag1 hatte keine Auswirkung auf das erhöhte Level von Neutrophilen und 
Eosinophilen in der bronchoalveolären Lavage von juvenilen Scnn1b-Tg Mäusen. Wir 
identifizierten eine erhöhte Genexpression des Zytokins Interleukin 17A in juvenilen 
Scnn1b-Tg Mäusen, welche in Scnn1b-Tg/Rag1-/- Mäusen reduziert war. Die 
Durchflusszytometrie zeigte, dass γδ T, CD4+ T Zellen und Typ 3 innate lymphoide 
Zellen Hauptquellen von Interleukin 17A in Lungen von Scnn1b-Tg Mäusen sind. Eine 
erhöhte Interleukin 17A Produktion hatte keinen Einfluss auf die Mukusobstruktion, 
konnte aber mit einer strukturellen Lungenschädigung bei juvenilen Scnn1b-Tg Mäusen 
assoziiert werden. 
Zusammenfassend unterstützen unsere Daten, dass die gestörte Clearance von 
inhalierten Allergenen eine wichtige Rolle bei der Pathogenese von Typ 2 
Atemwegsentzündungen spielt. Außerdem deuten sie darauf hin, dass die 
therapeutische Verbesserung der mukoziliären Clearance eine wirksame Strategie sein 
könnte, um krankheitsverschlimmernde Entzündungsreaktionen in Patienten mit 
allergischem Asthma und anderen chronischen Atemwegserkrankungen mit mukoziliärer 
Dysfunktion wie CF und COPD zu verhindern. Weiterhin liefern die Ergebnisse aus 
unserer Studie erste Einblicke in T und B zellabhängige Mechanismen, die zu 
pathophysiologischen Merkmalen der CF-Lungenkrankheit beitragen können. 
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1 Introduction 
1.1 Chronic airway diseases 
Mucus-obstructed airways are found in chronic lung diseases including rare genetic 
disorders such as CF and primary ciliary dyskinesia, as well as more common diseases 
such as COPD and asthma (Fahy and Dickey, 2010; Wanner et al., 1996). In healthy 
individuals, the airways are covered by a thin airway surface liquid (ASL) layer that 
consists of a complex mixture of mucins, proteins, lipids, ions and water (Button and 
Button, 2013; Fahy and Dickey, 2010). Most of these products are secreted by epithelial 
cells lining the airway surface as well as mucus-secreting submucosal glands in the 
larger airways (Livraghi and Randell, 2007). The ASL holds back invading bacteria, 
viruses, allergens and other environmental irritants that are constantly inhaled and 
deposited in the airways. By coordinated ciliary beating of ciliated cells, these noxious 
stimuli are removed from the lung (Button et al., 2012; Zhou-Suckow et al., 2017). 
Therefore, the MCC apparatus provides an important protective function and is one of 
the first lines of defense of the innate immune system in the lung. In mucus-obstructed 
airways such as CF and asthma, the MCC apparatus is impaired either by ASL 
dehydration due to ion imbalances and/or mucus hypersecretion and abnormal mucus 
rheology (Button et al., 2012; Evans et al., 2009; Hoegger et al., 2014). Consequences 
of impaired MCC and obstructed airways are chronic airway inflammation, 
bacterial/fungal colonization, airway remodeling, and structural lung damage (Zhou-
Suckow et al., 2017). 
1.1.1 Cystic fibrosis lung disease 
CF is an autosomal recessive disease and is one of the most frequent lethal genetic 
diseases in Caucasian population (Welsh et al., 2001). It is a multi-organ disease, but 
progressive lung disease continues to be the major cause of morbidity and mortality 
among CF patients (Ramsey, 1996). The disease is caused by a mutation in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene (Kerem et al., 1989; 
Riordan et al., 1989; Rommens et al., 1989). The CFTR protein is a multi-domain 
transmembrane protein functioning as an anion channel that conducts chloride (Cl-) and 
bicarbonate ions (Anderson et al., 1991; Smith and Welsh, 1992). The effects of the 
CFTR gene mutation vary from defective protein production, processing, regulation or Cl- 
conductance to reduced amounts of functioning CFTR protein in the plasma membrane 
(Mall and Hartl, 2014; Welsh and Smith, 1993). In the lung, CFTR is expressed on 
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airway surfaces and in submucosal glands (Jiang and Engelhardt, 1998). Impaired CFTR 
function leads to defective Cl- secretion and abnormal regulation of the epithelial sodium 
channel (ENaC) that constitutes the limiting pathway of sodium ion (Na+) and fluid 
absorption (Knowles et al., 1981; Mall et al., 1998). In the airways of CF patients, Cl- 
secretion is impaired and Na+ absorption is increased due to abnormal ENaC regulation 
resulting in elevated water absorption and ASL dehydration (Matsui et al., 2000; Matsui 
et al., 1998). Consequences of ASL depletion are impaired MCC, mucus-obstructed 
airways, chronic airway inflammation, microbial colonization and structural lung damage 
(Gibson et al., 2003; Mott et al., 2012; Rosenfeld et al., 2001). 
Microbial colonization of the airways by pathogens including Pseudomonas aeruginosa 
and Aspergillus fumigatus are a common phenomenon in patients with CF that further 
contributes to the severity of chronic airway inflammation (Hector et al., 2016). Some 
patients with CF also develop allergic bronchopulmonary aspergillosis (ABPA) which is 
an exaggerated response of the immune system to the fungus Aspergillus and is 
associated with type 2 immune responses that are similar to those seen in patients with 
allergic asthma in whom an increased risk to develop ABPA has also been observed 
(Knutsen and Slavin, 2011). It is assumed that impaired MCC and the emerging 
mucostatic environment might facilitate microbial colonization and its severe impact on 
chronic airway inflammation in CF and other muco-obstructive lung diseases. 
Chronic airway inflammation in CF lung disease is largely driven by neutrophils (Laval et 
al., 2016) and pro-inflammatory molecules predominantly produced by sources of the 
innate immune system (Courtney et al., 2004). Lately, efforts were undertaken to 
investigate the contribution of the adaptive immune system to chronic airway 
inflammation in CF lung disease. Specifically, T cells and their pro-inflammatory 
molecules came into the focus (Hubeau et al., 2004). Hector et al. demonstrated that the 
function of regulatory T cells is impaired in CF patients chronically infected with 
Pseudomonas aeruginosa (Hector et al., 2015). Further, studies indicated that CF lung 
disease might also be driven by the Th17 pathway and a Th2-skewed cytokine profile 
(Hartl et al., 2006; Hubeau et al., 2001; Tan et al., 2011; Tiringer et al., 2013); however, 
mechanistic insights into how impaired mucociliary clearance affects adaptive immunity 
and its effects on chronic airway inflammation in CF are poorly understood due to limited 
in vivo analysis and lack of animal models, as CFTR knockout mice failed to develop CF-
like lung disease (Grubb and Boucher, 1999). 
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1.1.2 Asthma 
Asthma is a chronic inflammatory disease that is one of the most common chronic lung 
disease among children causing approximately 250,000 deaths annually (Croisant, 2014; 
Gregory and Lloyd, 2011). The principal cause of death from asthma is asphyxiation 
from obstructed airways caused by mucus plugs (Aikawa et al., 1992; Messer et al., 
1960). The disease is very heterogenous and most patients, especially young children, 
suffer from atopic asthma (allergic asthma) that is indicated by a positive skin-prick test 
and the presence of IgE to common inhalant allergens, such as HDM, pollen, animal 
dander, and fungi (Barnes, 2008). 
A typical feature of allergic asthma is type 2 airway inflammation including eosinophilic 
airway inflammation, increased accumulation of Th2 cells and type 2 innate lymphoid 
cells (ILC2s) in the lung, and elevated levels of type 2 signature cytokines including IL-4, 
IL-5 and IL-13 (Neill et al., 2010; Robinson et al., 1992). Type 2 airway inflammation in 
asthmatic patients occurs when allergens encounter the airway lumen. Dendritic cells 
(DCs) take up the inhaled allergen and initiate Th2 cell responses, that are supported by 
basophils, mast cells, ILC2s, and B cells (Lambrecht and Hammad, 2012). Further, the 
airway epithelium is a central player during type 2 airway inflammation. Pattern 
recognition receptors on the epithelium sense the allergens and activate epithelial cells. 
Upon activation, epithelial cells produce endogenous danger signals including members 
of the IL-1 family IL-1α and IL-33, that could further activate DCs thereby bridging innate 
and adaptive immune signals to boost type 2 airway inflammation (Lambrecht and 
Hammad, 2012). Consequences of chronic airway inflammation in asthma are structural 
changes of the lung including an increase in the smooth muscle mass that is surrounded 
by the airway wall, and an increase of mucus-producing goblet cells in the epithelium or 
submucosal glands causing mucus hypersecretion (Benayoun et al., 2003; Evans et al., 
2009). Further, patients with asthma often develop airway hyperresponsiveness (AHR) 
which is the tendency of the airways to constrict in response to stimuli such as allergens, 
cold air, exercise, and other noxious stimuli (Brannan and Lougheed, 2012). 
Elevated levels of IL-13 are a major trigger for AHR and mucus hypersecretion 
(Kuperman et al., 2002; Zhu et al., 1999). Previous studies demonstrated that asthma is 
associated with impaired MCC that is especially highlighted in fatal asthma cases where 
severe airway mucus plugging is found (Hays and Fahy, 2003; Kuyper et al., 2003); 
notably, in patients with mild and stable asthma reduced MCC is also present (Bateman 
et al., 1983; Messina et al., 1991; Pavia et al., 1985). Mucociliary dysfunction can either 
be caused by defects in epithelial ion/fluid transport, as seen in patients with CF, or from 
mucus hypersecretion under conditions of chronic airway inflammation (Button et al., 
2012). Therefore, mucus hypersecretion might provide a potential mechanism as to how 
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mucociliary dysfunction occurs in asthma and other muco-obstructive lung diseases (Del 
Donno et al., 2000). Functional consequences of impaired MCC on chronic airway 
inflammation in patients with asthma are unknown and should not be underappreciated 
(Fahy and Dickey, 2010) as without an intact MCC apparatus, allergens and other 
noxious stimuli might accumulate and further boost chronic airway inflammation in 
patients with asthma. 
1.1.3 Chronic obstructive pulmonary disease 
COPD is one of the leading causes of morbidity and mortality worldwide (Mannino and 
Buist, 2007) and is especially prevalent in people with a history of tobacco smoking 
(Laniado-Laborin, 2009). Similar to asthma, COPD is also characterized by airway 
obstruction; however, in contrast to asthma, it is progressive and largely irreversible 
(Barnes, 2008). Characteristic pathogenic features of COPD are mucus-obstructed 
airways, chronic airway inflammation, and structural lung damage in the form of 
emphysema and chronic bronchitis (MacNee, 2005). 
Most COPD patients suffer from airway neutrophilia, elevated numbers of activated 
macrophages and Th1 immune responses (Sutherland and Martin, 2003). The secretion 
of pro-inflammatory mediators including proteases and cytokines induces structural 
changes of the lung including goblet cell metaplasia (GCM) with mucus hypersecretion 
and alveolar wall destruction (Barnes, 2008). 
In contrast to CF and asthma, mucus obstruction is mostly seen in the small airways of 
COPD patients and correlates with the increased goblet cell number and mucin gene 
expression (Innes et al., 2006). As in other chronic airway diseases, COPD is also 
associated with mucociliary dysfunction (Fahy and Dickey, 2010). Studies demonstrated 
that smoking tobacco inhibits CFTR function leading to an ion imbalance in the airway 
that facilitates ASL depletion (Raju et al., 2017). Another study demonstrated that highly 
concentrated mucus with increased percentage of solids and mucins caused by mucus 
hypersecretion resulted in ASL dehydration and mucociliary dysfunction in patients with 
chronic bronchitis (Anderson et al., 2015). Taken together, the underlying mechanisms 
leading to impaired MCC in COPD are variable but also share key mechanisms of other 
chronic airway diseases including CF and asthma. 
1.1.4 Mechanisms of impaired mucociliary clearance in chronic airway 
diseases 
As mentioned above, the MCC apparatus is an important innate defense mechanism of 
the lung. The hydration state of the ASL is crucial for an intact MCC (Button and Button, 
2013). The ASL covers the airway epithelium and consists of two layers, on top there is a 
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mucus layer, mainly consisting of the two mucins MUC5AC and MUC5B that is 
responsible for entrapping inhaled particles and irritants. Below the mucus layer, there is 
a periciliary layer (PCL) that is occupied by membrane-spanning mucins and large 
mucopolysaccharides that are tethered to cilia and the epithelial surface, and facilitates 
ciliary beating and cephalic mucociliary transport (Knowles and Boucher, 2002). 
Several mechanisms lead to impaired MCC in chronic lung diseases. A very common 
assumption is that ASL depletion, either caused by ion imbalances and/or by mucus 
hypersecretion leads to a compression of cilia resulting in impaired mucociliary transport 
(Button et al., 2012). In patients with CF, the ASL is depleted due to ion transport 
imbalances. The secretion of Cl- from the airway epithelium is impaired due to absence 
or defective CFTR function (Button and Button, 2013). Conversely, Na+ absorption is 
increased because of abnormal regulation of ENaC and hence water is actively 
absorbed from the airway lumen and the PCL and mucin layer are depleted of water 
leading to impaired MCC (Button et al., 2012; Clunes and Boucher, 2007). Mucus 
hypersecretion per se might also lead to a depletion of the ASL and impaired MCC. In 
asthma and COPD, elevated levels of mucus-inducing molecules including IL-13 and 
neutrophil elastase contribute to mucus hypersecretion (Barnes, 2008) and studies 
demonstrated that the increase of the osmotic pressure in the mucus layer by high 
mucus concentrations leads to an impairment or deformation of cilia and thus to a 
collapsed PCL resulting in reduced mucociliary transport (Anderson et al., 2015; Button 
et al., 2012). 
Besides the depletion of the ASL, other mechanisms also contribute to impaired MCC in 
chronic lung diseases. A study by Hoegger and colleagues found that mucociliary 
transport was reduced in airways of CF piglets and that the reduction is associated with 
CF submucosal glands secreted mucus strands that remained tethered to gland ducts 
and failed to detach (Hoegger et al., 2014). Another study by Chen et al. demonstrated 
that the defects in bicarbonate ion transport, as observed in CF airways, is associated 
with pathologically thick and viscid mucus that is not properly cleared from the lungs 
(Chen et al., 2010). Abnormal crosslinking of mucus via disulfide bonds due to oxidative 
stress triggered by chronic airway inflammation increases mucus elasticity and is also 
suggested to contribute to impaired MCC (Yuan et al., 2015). Elevated levels of IL-13 is 
one of many key pathologies in individuals with asthma. IL-13 induces GCM and mucus 
hypersecretion, especially of the mucin MUC5AC (Kuperman et al., 2002; Zhu et al., 
1999). Bonser et al. demonstrated that IL-13-induced MUC5AC expression impairs MCC 
in human bronchial epithelial cells due to MUC5AC-containing domains that are tethered 
to the airway epithelium slowing the mucociliary transport that might lead to progressive 
luminal accumulation of mucus and airway plugging in patients with asthma (Bonser et 
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al., 2016). Further, a recent study demonstrated that IL-13-induced inflammation 
increases Cl- secretion via an alternative Cl- channel. The lack of this channel was 
associated with mucus obstruction in IL-13-induced airway inflammation in vivo and a 
polymorphism in the gene reduced protein expression of the channel and was 
associated with asthma (Anagnostopoulou et al., 2012). 
Collectively, these observations demonstrated that various mechanisms contribute to 
impaired MCC in obstructive lung diseases and that the complex mechanisms between 
impaired MCC and chronic airway inflammation need to be further investigated. 
1.1.5 Mucociliary clearance as a therapeutic target 
As mentioned above, impaired MCC and/or excessive mucus production contribute to 
the pathogenesis of many chronic airway diseases including CF, asthma, and COPD and 
several studies demonstrated that pharmacological improvement of MCC is beneficial in 
patients with chronic lung diseases (Fahy and Dickey, 2010). 
Therapies that hydrate the ASL and thus improve MCC are very promising in patients 
with mucus-obstructed airways. The inhalation of 7 % hypertonic saline is a beneficial 
therapy already being used among patients with CF (Donaldson et al., 2006) and trials 
are under way for the treatment of other airway diseases including asthma and COPD. 
Hypertonic saline is thought to produce an osmotic gradient for water to move from the 
submucosa to the airway surface resulting in ASL hydration of airway surfaces (Matsui et 
al., 2000), thus improving MCC. Drugs that inhibit ENaC are also very promising 
candidates to improve ASL hydration not only in CF but also in other muco-obstructive 
lung diseases in which the ASL is depleted. The inhibition of ENaC leads to an increase 
of Na+ concentration in the airway lumen and thus is the osmotic driving force for water 
to hydrate the ASL (Althaus, 2013; Zhou et al., 2008). An aerosolized ENaC blocker is 
currently being evaluated for the improvement of airway hydration and MCC in CF in 
clinical trials (Scott et al., 2017). In CF, the basic defect is impaired Cl- secretion due to a 
mutation in the CFTR gene that leads to ASL dehydration and impaired MCC (Boucher, 
2002). CFTR modulators that aim to improve the function of mutant CFTR are currently 
in use or are in clinical trials (Ramsey et al., 2011; Van Goor et al., 2011). 
Besides therapies that improve ASL hydration, there are also therapies that target mucus 
rheology to improve MCC (Yuan et al., 2015). The breakage of disulfide bonds that 
convert mucin monomers to polymers and thus decreasing viscosity and elasticity of 
mucus seem to have an effect on MCC and need further development (Decramer and 
Janssens, 2010). 
Many efforts were undertaken to develop new therapies that target chronic airway 
inflammation in asthma including the development of antibodies that target the type 2 
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signaling cytokines IL-4, IL-5, and IL-13 (Swedin et al., 2017). Even though, improving 
MCC might have a beneficial effect for patients with asthma, little attention has been 
obtained to develop drugs that target impaired MCC, compared to the efforts undertaken 
to develop therapies that reduce chronic airway inflammation (Fahy, 2015). 
Glucocorticoids and bronchodilators are current treatments for asthma patients. The 
former inhibits the formation of goblet cells and mucus hypersecretion and the latter 
enlarges the luminal diameter that may improve MCC (Barnes, 2006). Hydration 
therapies might also be beneficial in asthma as mucus hypersecretion is a characteristic 
feature of asthma and might lead to ASL depletion and impaired MCC (Button et al., 
2012). 
In summary, these studies demonstrate that improvement of MCC is a beneficial 
treatment strategy for several chronic lung diseases with mucus-obstructed airways; 
however, mechanisms of impaired MCC are variable in those diseases and treatment 
strategies that target MCC need to be adjusted according to the underlying clearance 
defect to exploit their full therapeutic benefit. 
1.2 The Scnn1b-Tg mouse: A model to study the role of 
impaired mucociliary clearance in the pathogenesis of 
chronic airway diseases 
Scnn1b-Tg mice were originally developed to study the role of abnormal airway ion 
transport and airway surface dehydration in the pathogenesis of CF lung disease, as the 
CFTR knockout mice failed to develop characteristic pathogenic features of CF lung 
disease (Grubb and Boucher, 1999; Mall et al., 2004). In Scnn1b-Tg mice, the β-subunit 
of ENaC is specifically overexpressed in the airway epithelium under the control of the 
Club cell secretory protein promoter. ENaC is expressed in the luminal membrane of the 
airway epithelium and consists of three subunits α, β, and γ that are encoded by the 
genes Scnn1a, Scnn1b, and Scnn1c (Canessa et al., 1994). Airway-specific 
overexpression of the β-subunit leads to a congenital increase of Na+ and water 
absorption from the airway lumen that causes ASL depletion, mucus hyper-
concentration, and reduced MCC (Mall et al., 2004; Mall et al., 2008). Scnn1b-Tg mice 
share characteristic pathological features not only of CF lung disease but also of other 
obstructive lung diseases including COPD and asthma. A longitudinal study by Mall et al. 
showed that Scnn1b-Tg mice have an increased mortality due to airway mucus plugging 
in the first days of life and that newborn (3 to 5-days-old) Scnn1b-Tg mice develop early 
onset of chronic airway inflammation characterized by airway neutrophilia and elevated 
levels of the chemokine ligand 1 (CXCL1), a functional murine homolog of the human 
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cytokine IL-8 (Baggiolini et al., 1994). In juvenile Scnn1b-Tg mice, there is robust 
macrophage activation and a transient type 2 airway inflammation with increased levels 
of eosinophils and IL-13 that is superimposed by a neutrophilic airway inflammation and 
wanes at adult ages (Mall et al., 2008). In the first weeks of life, Scnn1b-Tg mice develop 
airway remodeling and mucus hypersecretion that is demonstrated by GCM and 
increased expression of the mucins Muc5ac and Muc5b (Mall et al., 2008). Chronic 
airway inflammation in Scnn1b-Tg mice is associated with emphysema-like structural 
lung damage including airspace enlargement and alveolar wall destruction together with 
airflow obstruction, increased lung compliance and a reduced density of lung 
parenchyma that was demonstrated by lung function studies and chest computed 
tomography, respectively (Gehrig et al., 2014; Mall et al., 2008; Trojanek et al., 2014; 
Wielputz et al., 2011). 
Data from these studies demonstrated that Scnn1b-Tg mice develop the full spectrum of 
pathophysiological phenotypes that are associated with mucus-obstructed lung diseases 
in humans (Boucher, 2002; Hogg, 1997; Hogg and Timens, 2009) and beyond this, 
provide a model to study mechanistic links between impaired MCC, mucus plugging, and 
chronic airway inflammation in the in vivo pathogenesis of chronic lung diseases. 
1.3 Aim of the thesis 
The overall aim of this study was to get further insights into the relationship between 
impaired MCC and airway inflammation in chronic airway diseases. 
Therefore, the first goal of this thesis was to investigate the relationship between 
impaired MCC and allergen-induced type 2 airway inflammation. Previous studies 
demonstrated that juvenile Scnn1b-Tg mice, with impaired MCC due to airway surface 
dehydration, develop spontaneous type 2 airway inflammation (Mall et al., 2008). These 
findings led us to hypothesize that impaired MCC causes reduced allergen clearance 
and might be a risk factor for the development of allergen-induced type 2 airway 
inflammation. To investigate our hypothesis, we analyzed allergen clearance 
mechanisms in juvenile WT and Scnn1b-Tg mice and validated the role of impaired MCC 
on allergen-induced type 2 airway inflammation by using intratracheal application of the 
natural aeroallergen HDM. In this model, we compared effects of impaired MCC on type 
2 airway inflammation including inflammatory cell counts and levels of type 2 cytokines in 
BAL, and AHR between juvenile WT and Scnn1b-Tg mice. Further, we determined 
effects of impaired MCC on allergen clearance and type 2 airway inflammation in adult 
mice. Finally, we examined, if pharmacological improvement of MCC by the inhibition of 
ENaC could prevent allergen-induced airway inflammation. 
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The second goal of this thesis was to characterize the relationship between impaired 
MCC and (dys)regulation of the adaptive immunity in the context of chronic airway 
diseases. Therefore, we crossed Scnn1b-Tg mice with Rag1-/- mice that lack mature T 
and B cells (Mombaerts et al., 1992) and analyzed juvenile Scnn1b-Tg/Rag1-/- double 
mutant mice for key pathologies of CF lung disease including airway inflammation, 
cytokine transcript expression and their cellular sources, mucus obstruction, and the 
development of structural lung damage.  
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2 Material and Methods 
2.1 Experimental animals 
All animal studies were approved by the Regierungspräsidium Karlsruhe, Germany (35-
9185.81/G-26/14). Scnn1b-Tg mice were studied on a C57BL/6N background. Rag1-/- 
mice (Jackson Laboratories, Bar Harbor, Me, USA) obtained on the C57BL/6N 
background were intercrossed with Scnn1b-Tg mice to obtain Scnn1b-Tg/Rag1-/-, 
Scnn1b-Tg, Rag1-/-, and WT littermates in the F2 generation. Mice were genotyped from 
tail biopsies by polymerase chain reaction (PCR) as previously described or as 
recommended by Jackson Laboratories (Mall et al., 2004). Animal experiments were 
performed at neonatal (10-day-old), juvenile (2- to 3-week-old), and adult (6-week-old) 
ages. Mice were housed in a specific pathogen-free animal facility with a standard 12 
hours day/night cycle at 22°C and had free access to food and water. 
2.2 Allergen exposure 
To mimic allergic airway inflammation, mice were exposed to Af extract (Hollister-Stier 
Laboratories, Spokane, Wash, USA) or HDM extract (Greer Laboratories, Lenoir, NC, 
USA) according to previously established protocols (Anagnostopoulou et al., 2010; 
Plantinga et al., 2013). In brief, mice were anesthetized with isoflurane (Baxter, 
Deerfield, Ill, USA) 3 % in oxygen and either Af or HDM dissolved in 0.9 % sodium 
chloride (NaCl) (B. Braun Melsungen AG, Melsungen, Germany) was administered by 
intratracheal instillation. In the Af protocol adult mice were intratracheally exposed to 50 
µl of Af (2 mg/ml) or 0.9 % NaCl alone every 48 hours a total of 4 times and sacrificed 24 
hours after the last allergen exposure. In the HDM protocol juvenile mice were 
intratracheally sensitized with 20 µl of HDM (0.5 mg/ml) or 0.9 % NaCl alone on two 
consecutive days, followed by two intratracheal challenges with 20 µl HDM (0.05 mg/ml) 
or 0.9 % NaCl alone on day 11 and 12 after the first HDM exposure and sacrificed 48 
hours after the last HDM challenge. For Af exposure during amiloride treatment, neonatal 
mice were challenged intratracheally with 20 µl Af (2 mg/ml) or 0.9 % NaCl alone. For 
HDM exposure during amiloride treatment, neonatal mice were sensitized with 10 µl 
HDM (1 mg/ml) or 0.9 % NaCl alone by intranasal instillations and challenged, as 
described above. 
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2.3 Amiloride treatment 
Amiloride studies were performed, as previously described (Zhou et al., 2008). In brief, 
newborn Scnn1b-Tg mice and WT littermates were treated by intranasal instillation of 
amiloride (10 mmol/l; 1μl/g body weight; 3 times per day) (Sigma-Aldrich, Taufkirchen, 
Germany) dissolved in double-distilled (dd) H2O or equal volumes of vehicle (ddH2O) 
alone for a period of three weeks. During intranasal amiloride treatment, mice were 
weighed 3 times per day to monitor for loss of body mass because of increased diuresis 
caused by renal effects of systemically absorbed amiloride. Volume deficits were 
replaced with subcutaneous injections of 0.9 % NaCl 3 times a day, as previously 
described (Zhou et al., 2008). In the third week of treatment, intranasal instillation was 
replaced by intratracheal instillation, and mice were additionally exposed to Af or HDM, 
as described above and shown in Figure 12A and Figure 13A. Mice were sacrificed 12 
hours after the last amiloride treatment. 
2.4 Airway hyperresponsiveness 
Measurements of respiratory resistance (Rrs) were performed by using a computer-
controlled small animal ventilator (flexiVent, SCIREQ, Montreal, Quebec, Canada) as 
previously described (Goplen et al., 2009). Mice were anesthetized by intraperitoneal 
injection of 80 mg/kg sodium pentobarbital (cp-pharma, Burgdorf, Germany). After the 
mice lost their foot-pad pinch response, a tracheostomy was performed and subjects 
were connected to the small animal ventilator through a 19-gauge intratracheal cannula. 
After initiating mechanical ventilation, mice were paralyzed by intraperitoneal injection of 
1.6 mg/kg pancuronium bromide (Inresa Arzneimittel GmbH, Freiburg, Germany). 
Animals were ventilated using the following settings: tidal volume of 10 ml/kg body 
weight, 150 breath/minute, and positive end-expiratory pressure approximately 2 to 3 cm 
H2O. Standardization of the lung volume history was performed by two deep inflations. 
Subsequently, measurements of Rrs were made. Measurements of resistance were 
determined from a user-defined protocol by using the snapshot-150 pertubation, which is 
a single-frequency sinusoidal waveform at a frequency equivalent to ventilation rate (i.e. 
2.5 Hz). Resultant data were fitted by using multiple linear regressions to the single 
compartment model, as previously described (Bates and Irvin, 2003; Irvin and Bates, 
2003; Shalaby et al., 2010). Changes in Rrs were measured in response to increasing 
concentrations of nebulized methacholine (Sigma-Aldrich, Taufkirchen, Germany) diluted 
in phosphate-buffered saline (PBS) from 0 to 160 mg/ml, and delivered into the 
inspiratory line of the flexiVent ventilator. Previous studies demonstrated that absolute 
Rrs is age- and weight-dependent in developing mice (Saglani et al., 2009). To adjust for 
this age- and weight-dependent variability of Rrs, AHR at different methacholine 
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concentrations was determined from percentage change of Rrs from baseline values (0 
mg/ml methacholine). In HDM-exposed Scnn1b-Tg mice severe airway obstruction and 
mucus plugging of cannulae impeded ventilation, and measurements had to be 
discontinued at high methacholine concentrations; > 32 mg/mL when Scnn1b-Tg mice 
were challenged with HDM alone (Figure 9) and > 80 mg/mL in studies with concurrent 
instillation of ddH2O 3 times per day (Figure 14). 
2.5 Bronchoalveolar lavage, differential cell counts and 
cytokine measurements 
Mice were deeply anesthetized by intraperitoneal injection with ketamine (120 mg/kg) 
(Bremer Pharma GmbH, Warburg, Germany) and xylazine (16 mg/kg) (cp-pharma, 
Burgdorf, Germany) and sacrificed by exsanguination. The trachea was cannulated, the 
left main stem bronchus was ligated and the lobes of the right lung were lavaged twice 
with sterile PBS (Thermo Fisher Scientific, Darmstadt, Germany) supplemented with 
proteinase inhibitor (Sigma-Aldrich, Taufkirchen, Germany) using a weight-adjusted 
volume of 0.0175 ml/g body weight. This weight-adjusted lavage volume approximates 
the vital capacity of a developing rodent lung and was used to account for differences in 
lung size (Lachmann et al., 1980; Shore et al., 2000). After BAL was performed, the right 
lung lobes were either inflated with fixative of 4 % buffered formalin (Otto Fischar, 
Saarbrücken, Germany) to 25 cm of fixative pressure, stored in 4 % buffered formalin at 
4°C overnight and used for measurements of distal airspace enlargement and alveolar 
wall destruction, or directly stored without inflation in RNAlater (Thermo Fisher Scientific, 
Darmstadt, Germany) at -80°C. The non-inflated left lobe from the same mouse was 
stored in 4 % buffered formalin at 4°C overnight and were used for measurements of 
airway mucus content. BAL was centrifuged at 300 x g for 5 minutes at 4°C (Eppendorf, 
Wesseling-Berzdorf, Germany) and cell-free supernatant was collected and stored 
at -80°C. Cells were suspended in 50 µl PBS, counted by trypan blue (Sigma-Aldrich, 
Taufkirchen, Germany) staining in a Neubauer counting chamber (Karl Hecht, Sondheim 
v. d. Rhön, Germany) and total cell counts per milliliter lavage fluid were determined by 
differential cell counts performed on May-Grünwald-Giemsa (Merck, Darmstadt, 
Germany) stained cytospin preparations, as previously described (Mall et al., 2008). For 
some experiments flow cytometry was used to determine differential cell counts from 
BAL and the method is described in detail in section 2.9.1. Concentration of cytokines IL-
4, IL-5, and IL-13 were measured in BAL supernatants by using cytometric bead array-
enhanced sensitivity flex set (BD Biosciences, Heidelberg, Germany) or ELISA (R&D 
Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions. 
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2.6 Mucociliary clearance 
Mice were anesthetized with intraperitoneal injection of 80 mg/kg sodium pentobarbital 
(cp-pharma, Burgdorf, Germany), the trachea was exposed by a median anterior neck 
incision, and the anterior wall was opened longitudinally to expose the mucosal surface 
(Figure 1). Yellow-green fluorescent microspheres (Thermo Fisher Scientific, Darmstadt, 
Germany) diluted in PBS with a diameter of 1.1 µm in a 2% solids solution 
(approximately 3.6 x 1010 microspheres/ml) were applied to the mucosal surface of the 
pars membranacea of the distal trachea (Figure 1). MCC was determined from imaging 
the elimination of fluorescent beads towards the larynx by using a DFC3000 G camera 
(Leica, Wetzlar, Germany) coupled to a MZ10 F modular stereo microscope (Leica, 
Wetzlar, Germany) and analyzed with Application Suite X software (Leica, Wetzlar, 
Germany). For quantification of MCC, the decrease in bead-derived fluorescent intensity 
was measured at the area of bead application, and percentage clearance at t = i minutes 
was calculated as follows: 
[1-fluorescence intensity at t = i minutes / fluorescence intensity at t = 0 minutes] x 100. 
 
 
Figure 1. Experimental setup of mucociliary clearance measurements. Mice were anesthetized and the 
trachea was exposed and the anterior wall was opened longitudinally. Fluorescent beads were applied to the 
mucosal surface of the trachea and the elimination of the fluorescent beads towards the larynx was 
monitored by an upright microscope. Bead application area is marked with a blue line and the beads are 
shown in green. 
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2.7 Whole-lung and airway allergen clearance 
Whole-lung and airway allergen clearance was assessed by measuring the elimination of 
fluorescently labeled Af after intratracheal instillation. Af was fluorescently labeled with 
Alexa Fluor 647 Microscale Protein Labeling Kit (Thermo Fisher Scientific, Darmstadt, 
Germany), according to the manufacturer’s instructions. Mice were anesthetized with 
isoflurane (Baxter, Deerfield, Ill, USA) 3 % in oxygen, and 2.5 µg of fluorescently labeled 
Af was intratracheally administered in a volume of 20 µL dissolved in PBS. To determine 
whole lung allergen clearance mice were sacrificed by exsanguination after deep 
anesthesia through intraperitoneal injection of 120 mg/kg ketamine (Bremer Pharma 
GmbH, Warburg, Germany) and 16 mg/kg xylazine (cp-pharma, Burgdorf, Germany) 
either immediately (t = 0 hours) or 1 hour after allergen instillation. Lungs and trachea 
(up to but not including the larynx) were excised, placed in tubes containing 500 µl PBS 
supplemented with proteinase inhibitor (Sigma-Aldrich, Taufkirchen, Germany), and 
tissue was homogenized by a tissue homogenizer (IKA, Staufen, Germany). 
Homogenized material was analyzed by a plate reader (Perkin Elmer, Waltham, Mass, 
USA) for fluorescence intensity. Baseline (t = 0 hours) fluorescence intensity (arbitrary 
units) was assessed by averaging the fluorescence signal in lungs of mice euthanized 
immediately after instillation. These baseline values were not significantly different 
between WT (10,525 ± 953, n = 6) and Scnn1b-Tg (10,896 ± 877, n = 5, P = 0.78) mice. 
To determine allergen clearance from the airways, BAL was performed with a volume of 
500 µl PBS supplemented with proteinase inhibitor (Sigma-Aldrich, Taufkirchen, 
Germany) either immediately (t = 0) or 1 hour after allergen instillation. Again baseline 
(t = 0 hours) intensity (arbitrary units) did not differ between WT (17,658 ± 1949, n = 6) 
and Scnn1b-Tg (17,492 ± 1677, n = 7, P = 0.87) mice. For quantification of whole lung 
and airway allergen clearance, the decrease in allergen-derived fluorescent intensity was 
measured in lung homogenates and BAL supernatants, respectively. Percentage 
clearance after 1 hour was calculated by the following formula: 
[1 - fluorescence intensity at t = 1 hour / fluorescence intensity at t = 0 hours] x 100. 
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2.8 Allergen uptake 
In vivo Af uptake by airway macrophages (AMs) and conventional dendritic cells (cDCs) 
was determined, as previously described (Lauzon-Joset et al., 2014; Soroosh et al., 
2013). In brief, Mice were anesthetized with isoflurane (Baxter, Deerfield, Ill, USA) 3 % in 
oxygen, and 2.5 µg of fluorescently labeled Af was intratracheally administered in a 
volume of 20 µl dissolved in PBS. Four hours after instillation, whole lung was lavaged 
twice with PBS using a weight-adjusted volume of 0.035 ml/g body weight. 
Subsequently, BAL was processed as described in section 2.9.1. Allergen uptake by 
AMs and cDCs was assessed by determining the frequency of Af-Alexa Fluor 647-
positive cells with a BD LSRFortessa cell analyzer (BD Biosciences, Heidelberg, 
Germany) and FACSDiva software v8.0.1 (BD Biosciences, Heidelberg, Germany). For 
in vitro allergen uptake, BAL was performed and centrifuged at 300 x g for 5 minutes at 
4°C. BAL supernatant was discarded, cells were washed twice with PBS, and 50,000 
cells were suspended in 100 µl RPMI-1640 medium (GE Healthcare Life Sciences, 
South Logan, UT, USA) and 1.25 µg labeled Af was added in a volume of 10 µl of PBS. 
Cells were incubated for 4 hours at 37°C and 5 % CO2, and allergen uptake by AMs and 
cDCs was assessed, as described for in vivo allergen uptake. 
2.9 Flow cytometry 
2.9.1 Preparation of BAL cells for flow cytometric analysis 
BAL was transferred in a 5-ml polystyrene round-bottom tube (BD Biosciences, 
Heidelberg, Germany) and centrifuged at 300 x g for 5 minutes at 4°C (Thermo Fisher 
Scientific, Darmstadt, Germany). Cell-free supernatant was collected and stored 
at -80°C. Subsequently, 500 µl of PBS and 2 ml nuclease-free H2O (Thermo Fisher 
Scientific, Darmstadt, Germany) containing 10 % sputolysin (Merck, Darmstadt, 
Germany) were added and BAL cells were incubated for 15 minutes at room 
temperature, and repeatedly vortexed to release cells from mucus. A volume of 2 ml 
fluorescence-activated cell sorting (FACS) buffer, containing PBS substituted with 1 % 
inactivated fetal bovine serum (FBS) (Thermo Fisher Scientific, Darmstadt, Germany) 
and 0.09 % sodium azide (Sigma-Aldrich, Taufkirchen, Germany), was added and cells 
were centrifuged at 300 x g for 5 minutes at 4°C. Supernatant was discarded and cells 
were again washed with 4 ml FACS buffer. Finally, cells were suspended in 70 µl of 
FACS buffer and total cell numbers and viability were assessed by trypan blue (Sigma-
Aldrich, Taufkirchen, Germany) exclusion test. Cell surface staining was performed with 
50 µl of cell suspension. Before surface staining with specific monoclonal fluorochrome-
conjugated antibodies or respective isotype control antibodies, cells were incubated with 
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1 µl FcBlock (BD Biosciences, Heidelberg, Germany) for 5 minutes at room temperature. 
A master mix of the antibodies listed in Table 1 was prepared, added to the cell 
suspension and incubated for 30 minutes at 4°C in the dark. 
Table 1. Antibody master mix for the detection of myeloid and lymphoid cells in BAL by flow 
cytometry 
Antibody Clone Fluorophore Supplier Dilution 
F4/80* BM8 
Allophycocyanin 
(APC)-Cy7 
Biolegend 1:100 
MHCII M5/114.15.2 eFluor 450 eBioscience 1:400 
Siglec-F E50-2440 
Phycoerythrin 
(PE)-CF594 
BD Biosciences 1:50 
CD11c HL3 PE-Cy7 BD Biosciences 1:200 
CD11b M1/70 
Brilliant violet (BV) 
605 
Biolegend 1:100 
CD206 MR5D3 PE Bio-Rad 1:20 
Gr1 RB-8C5 
Peridinin- 
chlorophyll-protein 
complex (PerCP)-
cyanine (Cy) 5.5 
eBioscience 1:50 
CD64* X54-5/7.1 APC Biolegend 1:50 
CD3e 500A2 V500 BD Biosciences 1:50 
CD4 RM4-5 
Fluorescein 
isothiocyanate 
(FITC) 
eBioscience 1:50 
CD8a* 53-6.7 Alexa fluor 700 eBiosciences 1:50 
*For the detection of allergen uptake by AMs and cDCs, the master mix was prepared without the antibodies 
against CD64, F4/80, and CD8a. 
 
Cells were washed in FACS buffer and flow cytometry was performed on a BD 
LSRFortessa cell analyzer (BD Biosciences, Heidelberg, Germany) immediately after 
cellular staining with exclusion of debris and cell-doublets, and data were analyzed with 
FACSDiva software (v8.0.1; BD Biosciences, Heidelberg, Germany) or Flow Jo software 
(v10; TreeStar, Ashland, OR, USA) using the gating strategy shown in Figure 2. 
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Figure 2. Gating strategy for the detection of myeloid and lymphoid cells in bronchoalveolar lavage 
by flow cytometry. BAL cells were prepared according to the protocol described above and applied to flow 
cytometry. BAL cells were characterized as follows: CD4+ T cells (CD3e+, CD4+, F4/80-, and CD11c-), CD8+ 
T cells (CD3e+, CD8a+, F4/80-, and CD11c-), neutrophils (CD11b+, Gr1+, CD3-, and F4/80-), conventional 
dendritic cells (cDCs) (CD11c+, MHCIIhigh, CD3-, Gr1- and SiglecF-), eosinophils (Siglec-F+, CD11b+, CD11c-, 
Gr1-, and CD3-), airway macrophages (AMs) (Siglec-F+, CD11c+, MHCIImid, CD64+, F4/80+, and CD3-). 
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2.9.2 Preparation of single cells from lung tissue for flow cytometric 
analysis 
For isolation of leukocytes from the lungs, mice were deeply anesthetized through 
intraperitoneal injection of 120 mg/kg ketamine (Bremer Pharma GmbH, Warburg, 
Germany) and xylazine (16 mg/kg) (cp-pharma, Burgdorf, Germany) and killed by means 
of exsanguination, and the lungs were perfused trough the right ventricle of the heart 
with 10 ml PBS, removed, and placed in RPMI-1640 medium (GE Healthcare Life 
Sciences, South Logan, UT, USA) on ice for immediate processing. Each lung was 
removed from RPMI-1640 medium, placed into a petri dish (Greiner Bio-One, 
Frickenhausen, Germany) and trachea, esophagus, and connective tissue were removed 
from peripheral lung tissue which was then minced with scissors into pieces no larger 
than 2 to 3 mm, transferred to a 50-ml conical tube (Sarstedt, Nümbrecht, Germany) with 
10 ml of PBS containing 300 U/ml collagenase type II (Worthington Biochemical, 
Lakewood, NJ, USA) and 0.15 mg/ml Deoxyribonuclease (DNase) I (Sigma-Aldrich, 
Taufkirchen, Germany), and incubated for 30 minutes at 37°C, as previously described 
(Sauer et al., 2006). Digested lung solutions were passed through a 100-µm mesh 
(Sigma-Aldrich, Taufkirchen, Germany) which was then rinsed with 10 ml cold PBS to 
stop DNase reaction. Subsequently, lung solutions were centrifuged at 300 x g for 
5 minutes at 4°C, supernatant was discarded and cells were incubated in 5 ml of red 
blood cell lysis buffer (BD Biosciences, Heidelberg, Germany) for 5 minutes at room 
temperature and transferred through a 40-µm mesh (Sigma-Aldrich, Taufkirchen, 
Germany) which was then rinsed with 10 ml RPMI-1640 medium (GE Healthcare Life 
Sciences, South Logan, UT, USA). Single cells were finally suspended in cRPMI medium 
containing RPMI-1640, 10 % FBS (Thermo Fisher Scientific, Darmstadt, Germany), 
0.1 % 2-Mercaptoethanol (Thermo Fisher Scientific, Darmstadt, Germany), 1 % 
L-Glutamin (Thermo Fisher Scientific, Darmstadt, Germany). Total cell numbers and 
viability were assessed by trypan blue (Sigma-Aldrich, Taufkirchen, Germany) exclusion 
test. For detection of intracellular IL-17A and RAR-related orphan receptor gamma t 
(RORγt) expression, cells were centrifuged at 300 x g for 5 minutes at 4°C, supernatant 
was discarded and cells were suspended at a concentration of 2 x 106 cells/190 µl in 
cRPMI medium containing 30 ng/ml phorbol 12-myristse 13-acetate (PMA) (Sigma-
Aldrich, Taufkirchen, Germany) and 500 ng/ml ionomycin (Sigma-Aldrich, Taufkirchen, 
Germany). A volume of 190 µl of single-cell suspension was loaded into 96-well plates 
(Corning, Big Flats, NY, USA) together with 10 µl of BD Golgi-Stop (BD Biosciences, 
Heidelberg, Germany) and stimulated in vitro for 4 hours at 37°C and 5 % CO2. Cells 
were then gently removed from wells and transferred to 5-ml polystyrene round-bottom 
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tube (BD Biosciences, Heidelberg, Germany), 1 ml FACS buffer was added, centrifuged 
at 300 x g for 5 minutes at 4°C and finally resuspended in 100 µl FACS buffer. Before 
surface staining with specific monoclonal fluorochrome-conjugated antibodies or 
respective isotype control antibodies, cells were incubated with 1 µl FcBlock (BD 
Biosciences, Heidelberg, Germany) for 5 minutes at room temperature. For surface 
staining, a master mix of the antibodies listed in Table 2 was prepared, added to the cell 
suspension and incubated for 30 minutes at 4°C in the dark. 
Table 2. Antibody master mix for the detection of lung-derived IL-17A+ leukocytes by flow cytometry 
Antibody Clone Fluorophore Supplier Dilution 
CD45 30-F11 V500 BD Biosciences 1:100 
CD4 RM4-5 FITC eBioscience 1:100 
CD8a 53-6.7 PE-CF594 BD Biosciences 1:100 
CD3e 145-211 BV421 BD Biosciences 1:100 
NK1.1 PK136 BV605 BD Biosciences 1:100 
γδTCR GL3 APC eBioscience 1:100 
Lineage Marker: 
CD19 
GR1 
CD11c 
CD11b 
 
1D3 
RB6-8C5 
HL3 
M1/70 
 
 
Alexa Fluor 700 
 
 
 
BD Biosciences 
BD Biosciences 
BD Biosciences 
eBioscience 
 
1:100 
1:100 
1:100 
1:100 
 
Cells were then washed with 2 ml PBS and resuspended in 1ml PBS and 0.75 µl fixable 
viability dye eFluor 780 (eBioscience, Darmstadt, Germany) was added and incubated 
for 25 minutes at 4°C in the dark. After two washing steps with 2 ml FACS buffer each, 
cells were fixed and permeabilized with Foxp3/Transcription factor staining buffer set 
(eBioscience, Darmstadt, Germany) according to manufacturer’s instructions and 
subsequently incubated with 1 µl IL-17A-PE (clone TC11-18H10) (BD Biosciences, 
Heidelberg, Germany) and 1 µl of 1:5 pre-diluted in FACS buffer RORγt-PerCP-eFluor 
710 (clone B2D) (eBioscience, Darmstadt, Germany) antibody for 30 minutes at room 
temperature. Finally, cells were washed in FACS buffer and flow cytometry was 
performed on a BD LSRFortessa cell analyzer (BD Biosciences, Heidelberg, Germany) 
and data were analyzed with FACSDiva software (v8.0.1; BD Biosciences, Heidelberg, 
Germany) or Flow Jo software (v10; TreeStar, Ashland, OR, USA) and the following 
gating strategy (Figure 3) was applied to identify IL-17A producing leukocytes. 
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Figure 3. Gating strategy for the detection of lung-derived IL-17A-producing leukocytes by flow 
cytometry. Single cell suspension from lungs of mice was prepared, stimulated with PMA and ionomycin, 
and stained according to the protocol described above. IL-17A producing leukocytes were described as 
follows: Natural killer(NK) and NKT cells (CD45+, IL-17A+, and NK1.1+), γδ T cells (CD45+, IL-17A+, CD3e+, 
γδTCR+, and NK1.1-), CD4+ T cells (CD45+, IL-17A+, CD3e+, CD4+, NK1.1-, γδTCR-, and CD8a-), CD8+ T 
cells (CD45+, IL-17A+, CD3e+, CD8a+, NK1.1-, γδTCR-, and CD4-), ILC3s (CD45+, IL-17A+, RORγt+, lineage-, 
NK1.1-, and CD3-). Lineage marker includes CD19, Gr1, CD11c, and CD11b. 
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2.10 Histology and morphology 
2.10.1 Tissue embedding and preparation of tissue sections 
Fixed lungs were washed in PBS and either stored in 70 % ethanol (Carl Roth, 
Karlsruhe, Germany) at 4°C or directly processed for paraffin embedding. In brief, the 
apical part of the fixed lungs was cropped transversally and lungs were placed in 
embedding cassettes (Steinbrenner Laborsysteme, Wiesenbach, Germany) and 
dehydrated 2 x 30 minutes in 96 % ethanol (Carl Roth, Karlsruhe, Germany), 2 x 45 
minutes in 100 % ethanol (Carl Roth, Karlsruhe, Germany), and 12 to 16 hours in xylene 
(Carl Roth, Karlsruhe, Germany). Samples were then submerged in paraffin (Carl Roth, 
Karlsruhe, Germany) and vacuum was applied for 2 hours followed by 1 hour at 
atmospheric pressure. Afterwards, lungs were placed in embedding molds with the 
cropped surface facing downwards to ensure correct orientation of embedded tissue. 
Paraffin blocks were kept for 12 to 16 hours at 4°C to harden completely. Left lungs were 
cut with a microtome (Leica Microsystems, Nussloch, Germany) to 5 µm and were 
sectioned transversally at the level of the proximal intra-pulmonary main axial airway 
near the hilus. Right lung lobes were cut to sections of 5 µm. Lung sections were 
deparaffinized in xylene (Carl Roth, Karlsruhe, Germany) and rehydrated 2 x 10 minutes 
in 100 % ethanol (Carl Roth, Karlsruhe, Germany), 2 x 2 minutes in 96 % ethanol (Carl 
Roth, Karlsruhe, Germany), 2 minutes in 70 % ethanol (Carl Roth, Karlsruhe, Germany), 
and finally rinsed in ddH2O. 
2.10.2 Airway mucus content 
For morphometric analysis of airway mucus content, 5 μm sections from the left lung 
lobe were stained with Alcian blue periodic acid-Schiff (AB-PAS). In brief, tissue sections 
were placed in Alcian blue solution containing 3 % acetic acid (Carl Roth, Karlsruhe, 
Germany), 1 % Alcian Blue 8GX (Sigma-Aldrich, Taufkirchen, Germany), and 2 to 3 
crystals of Thymol (Sigma-Aldrich, Taufkirchen, Germany) for 30 minutes, rinsed 2 
minutes in tab water, and transferred to 0.5 % periodic acid solution (Sigma-Aldrich, 
Taufkirchen, Germany) for 5 minutes. Subsequently, sections were rinsed 3 x in ddH2O, 
placed 15 minutes in Schiff’s reagent (Sigma-Aldrich, Taufkirchen, Germany) and 1 
minute in sulfur solution containing 1 % 5 M HCl (Merck, Darmstadt, Germany), 0.6 % 
sodium metabisulfit (Sigma-Aldrich, Taufkirchen, Germany). Tissue was again rinsed 
with tab water and dehydrated 1 minute in 96 % ethanol (Carl Roth, Karlsruhe, 
Germany), followed by 2 x 1 minute in 100 % ethanol (Carl Roth, Karlsruhe, Germany) 
and 3 minutes in xylene (Carl Roth, Karlsruhe, Germany), and finally mounted with 
permanent mounting medium (Sigma-Aldrich, Taufkirchen, Germany). Images of stained 
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airway sections were taken with an Olympus IX-71 microscope (Olympus, Hamburg, 
Germany) interfaced with a DP73 camera (Olympus, Hamburg, Germany) and analyzed 
using Cell F imaging software (OSIS, Münster, Germany). Intraluminal airway mucus 
content was determined in 5 μm sections, as previously described (Harkema et al., 
1987). In brief, the area of luminal AB-PAS positive material in the airway was quantified 
using a defined threshold and related to the area of the airway, which was derived from 
the length of the luminal membrane of the airway epithelium. This ratio was then 
normalized to the surface area per unit volume (Harkema et al., 1987; Mall et al., 2008; 
Weibel, 1963). 
2.10.3 Mean linear intercepts and destructive index 
The 4 right lung lobes were washed in PBS and connective tissue, trachea, and 
esophagus were removed. Right lung lobes were either stored in 70 % ethanol (Carl 
Roth, Karlsruhe, Germany) at 4°C or directly processed for paraffin embedding, 
sectioned, deparaffinized, and rehydrated, as described above. Lung sections were then 
stained with hematoxylin and eosin to determine mean linear intercepts as a measure of 
distal airspace enlargement and destructive index as a measure of alveolar wall 
destruction. In brief, tissue slides were placed 3 minutes in hematoxylin (Sigma-Aldrich, 
Taufkirchen, Germany), rinsed with ddH2O and placed 1 minute in HCl/ethanol solution 
containing 50 % ethanol (Carl Roth, Karlsruhe, Germany) and 1.3 % 5 M HCl (Merck, 
Darmstadt, Germany), and subsequently washed with tab water. Slides were then 
transferred to the eosin solution containing 0.1 % Eosin (Carl Roth, Karlsruhe, 
Germany), 63 % ethanol (Carl Roth, Karlsruhe, Germany), and 1 % acetic acid (Carl 
Roth, Karlsruhe, Germany), for 45 seconds before rinsing again in ddH2O. Tissue 
sections were then dehydrated, and mounted with permanent mounting medium (Sigma-
Aldrich, Taufkirchen, Germany), as described above. For measurement of alveolar 
airspace enlargement and alveolar wall destruction, images of randomly selected airway 
sections were taken with an Olympus IX-71 microscope (Olympus, Hamburg, Germany) 
interfaced with a DP73 camera (Olympus, Hamburg, Germany) at 10x magnification. 
Images were analyzed using Cell F image analysis software (OSIS, Münster, Germany). 
For the analysis of mean linear intercepts the line counting tool beginning at a randomly 
selected point was used. Mean linear intercepts were determined by dividing the sum of 
the lengths of all lines in all frames by the number of intercepts between alveolar septi 
and counting lines, as previously described (Dunnill, 1962). For each animal, we 
measured a minimum of 200 intercepts sampled in 10 fields in different lobes. The 
destructive index was determined using a grid of 72 points overlying images of lung 
sections. The points were classified to lie within destructed (D) or intact (N, normal) 
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alveolar ducts in the lung parenchyma and the destructive index was calculated by the 
formula: 100 x D / (D + N) as previously described (Saetta et al., 1985). For each animal, 
a minimum of 250 points was sampled and classified in 10 fields in different lobes. 
2.11 RNA extraction and real-time RT-PCR 
2.11.1 RNA extraction 
Lungs were transferred in 1 ml Trizol reagent (Thermo Fisher Scientific, Darmstadt, 
Germany) and tissue was homogenized by a tissue homogenizer (IKA, Staufen, 
Germany). Samples were left at room temperature for 20 minutes. Subsequently, 200 µl 
chloroform (Sigma-Aldrich, Taufkirchen, Germany) was added and samples were 
vortexed for 15 seconds, left at room temperature for 2 to 3 minutes, and centrifuged at 
14,000 x g for 20 minutes at 4°C. Upper aqueous phase was transferred to a fresh tube 
and 500 µl isopropanol (Carl Roth, Karlsruhe, Germany) was added and vortexed 
thoroughly for 10 seconds, following incubation for 30 minutes at -20°C. Samples were 
then centrifuged at 16,000 x g for 10 minutes at 4°C and supernatant was discarded. 
Pellet was washed with 1 ml 80 % ethanol (Carl Roth, Karlsruhe, Germany) and 
centrifuged at 16,000 x g for 5 minutes at 4°C. Supernatant was again discarded and 
pellets were air-dried before dissolving them in nuclease-free H2O (Thermo Fisher 
Scientific, Darmstadt, Germany). RNA concentration and purity were measured by a 
spectrophotometer (DeNovix, Wilmington, DE, USA). 
2.11.2 Real-time RT-PCR 
cDNA was obtained by performing reverse transcription (RT) of 2 μg of total RNA with 
Superscript III reverse transcriptase (Thermo Fisher Scientific, Darmstadt, Germany) 
according to manufacturer’s instructions. Real-time quantitative PCR was performed on 
an Applied Biosystems 7500 Real Time PCR system with TaqMan Universal PCR 
master mix and inventoried TaqMan gene expression assays (Applied Biosystems, 
Darmstadt, Germany) for Muc5ac (Mm01276718_m1), Muc5b (Mm00466391_m1), 
chloride channel accessory 1 (Gob5) (Mm01320697_m1), Interferon γ (Ifnγ) 
(Mm01168134_m1), Il6 (Mm00446190_m1), Cxcl1 (Mm04207460_m1), Il4 
(Mm00445259_m1), Il5 (Mm00439646_m1), Il13 (Mm00434204_m1), Il17a 
(Mm00439618_m1), matrix metalloproteinase 12 (Mmp12) (Mm00500554_m1), acitic 
mammalian chitinase (Chia) (Mm00458221_m1), chitinase-like 3 (Ym1) 
(Mm00657889_mH), chitinase-like 4 (Ym2) (Mm00840870_m1), arginase 1 (Arg1) 
(Mm00475988_m1), and β-Actin (Actb) (Mm00607939_s1) according to manufacturer’s 
instructions (purchased all from Thermo Fisher Scientific, Darmstadt, Germany). Relative 
fold changes in target gene expression were calculated from the efficiency of the PCR 
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reaction and the crossing point deviation between samples from the different genotypes 
in relation to wild-type controls and normalization to the expression of the reference gene 
Actb, as previously described (Pfaffl, 2001). 
2.12 Statistics 
Data were derived from at least 3 independent experiments and were analyzed with 
SigmaPlot version 12.5 software (Systat Software, Erkrath, Germany) and reported as 
mean ± SEM. Statistical analysis was performed with one-way ANOVA and Tukeyʼs post 
hoc test, Kruskal-Wallis ANOVA and Dunnʼs post hoc test, unpaired t-test, and Mann 
Whitney U test, as appropriate. P < 0.05 was accepted to indicate statistical significance. 
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3 Results 
3.1 Role of mucus clearance as innate defense mechanism of 
the lung in allergen-induced airway inflammation 
Previous studies demonstrated that asthma is associated with impaired MCC (Bateman 
et al., 1983; Messina et al., 1991; Wanner et al., 1996) and studies from our group 
showed that impaired MCC in juvenile Scnn1b-Tg mice produces spontaneous type 2 
airway inflammation, including increased levels of the type 2 signature cytokine IL-13, 
airway eosinophilia and mucus hypersecretion (Mall et al., 2008). In preliminary studies, 
we observed that a short-term allergen challenge protocol consisting of 4 Af challenges, 
induces an exaggerated type 2 airway inflammation with increased levels of the type 2 
signature cytokines IL-4, IL-5 and IL-13, airway eosinophilia, and AHR in juvenile 
Scnn1b-Tg mice (Fritzsching et al., 2017). To investigate the effects of impaired MCC on 
allergen clearance and type 2 airway inflammation, we analyzed allergen clearance 
mechanisms in WT and Scnn1b-Tg mice and evaluated the role of impaired MCC in 
another allergen model by using a protocol consisting of HDM sensitization and 
challenge in juvenile WT and Scnn1b-Tg mice. Further, we tested age-dependent 
susceptibility of allergen-induced type 2 airway inflammation. Finally, as a proof of 
concept, we examined if pharmacological improvement of MCC might be an effective 
therapeutic strategy to reduce allergic airway inflammation. 
3.1.1 Mucociliary clearance, whole-lung and airway allergen clearance are 
reduced in juvenile Scnn1b-Tg mice 
To assess MCC in WT and Scnn1b-Tg mice, we used an in vivo fluorescent bead assay 
which was based on the elimination of fluorescent microspheres from the trachea. 
Consistent with previously published results (Mall et al., 2008), we observed a reduced 
MCC in Scnn1b-Tg mice (Figure 4). To determine the effects of mucociliary dysfunction 
on allergen clearance, we instilled fluorescently labeled Af in juvenile naïve WT and 
Scnn1b-Tg mice and measured the allergen clearance from the whole lung and airway 
lumen. Both whole-lung and airway allergen clearance were decreased in Scnn1b-Tg 
mice (Figure 5). Overall, these data demonstrate that impaired MCC leads to reduced 
allergen clearance from the lungs of Scnn1b-Tg mice. 
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Figure 4. Impaired mucociliary clearance in Scnn1b-Tg mice. (A and B) Mice were anesthetized, the 
trachea was exposed and the anterior wall was opened longitudinally to expose the mucosal surface. 
Fluorescent microspheres were applied to the mucosal surface and mucociliary clearance was determined 
from imaging the elimination of fluorescent beads toward the larynx. (A) Microscopic images of fluorescent 
beads (green) at t = 0 minutes (min.) and t = 1 min. in WT and Scnn1b-Tg mice. (B) Percent of cleared 
fluorescent beads over a period of 6 min. in WT and Scnn1b-Tg mice. n = 4 mice for each group. *P < 0.05, 
**P < 0.01, and ***P < 0.001 compared with WT mice. 
 
Figure 5. Mucociliary dysfunction impairs allergen clearance in juvenile Scnn1b-Tg mice. (A and B) 
Fluorescently labeled Af was intratracheally instilled in juvenile WT and Scnn1b-Tg mice and elimination 
from either whole-lung (A) or airways (B) was measured after 1 hour. n = 6-7 mice for each group. **P < 0.01 
compared with WT mice. 
  Results 
  27 
3.1.2 Altered allergen uptake by airway macrophages and conventional 
dendritic cells in juvenile Scnn1b-Tg mice 
AMs and cDCs are one of the first cell types encountered by aeroallergens in the airways 
and are important for the removal and the presentation of the allergen to T cells (Balhara 
and Gounni, 2012; Hammad and Lambrecht, 2008). Because whole-lung and airway 
allergen clearance are impaired in Scnn1b-Tg mice, we investigated the capacity of 
allergen uptake by AMs and cDCs in vivo and in vitro. Af was fluorescently labeled and 
either instilled by intratracheal application in juvenile WT and Scnn1b-Tg mice for in vivo 
allergen uptake or incubated together with BAL cells for in vitro allergen uptake and flow 
cytometry was performed to analyze the capacity of allergen uptake by cDCs and AMs. 
The uptake of fluorescently labeled Af by AMs from naïve Scnn1b-Tg mice was impaired 
and significantly decreased compared with that in WT mice in vivo and in vitro (Figure 6). 
 
 
Figure 6. Reduced allergen uptake by airway macrophages in juvenile Scnn1b-Tg mice. (A-C) Allergen 
uptake by airway macrophages (AMs) was assessed by determining the frequency of Af-Alexa Fluor 647-
positive cells by flow cytometry in juvenile WT and Scnn1b-Tg mice. (A) Representative dot plots of WT and 
Scnn1b-Tg AMs (Siglec-F+/CD11c+/MHCIImid) and lymphocytes (Siglec-F-/CD11c-). Number in rectangles 
represents percentage of AMs that are positive or negative for Af. (B and C) Percentage of BAL fluid-derived 
AMs from WT and Scnn1b-Tg mice positive for fluorescently labeled Af after intratracheal application in vivo 
(B) or incubation in vitro (C). n = 5-6 mice for each group. *P < 0.05 compared with WT mice. 
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Figure 7. Increased allergen uptake by conventional dendritic cells in juvenile Scnn1b-Tg mice. 
(A and B) Allergen uptake by conventional dendritic cells (cDCs) was assessed by determining the frequency 
of Af-Alexa Fluor 647-positive cells by flow cytometry and the percentage of BAL fluid-derived cDCs 
(CD11c+/MHCIIhigh/Siglec-F-) from juvenile WT and Scnn1b-Tg mice positive for fluorescently labeled Af after 
intratracheal application in vivo (A) or incubation in vitro (B). n = 5-6 mice for each group. *P < 0.05 and 
***P < 0.001 compared with WT mice. 
Conversely, uptake of Af by lung cDCs was significantly enhanced in Scnn1b-Tg mice 
(Figure 7). Collectively, these data show that impaired MCC facilitates reduced allergen 
clearance resulting in altered allergen uptake of AMs and cDCs. 
3.1.3 Impaired mucus clearance exacerbates HDM-induced type 2 airway 
inflammation and AHR in juvenile Scnn1b-Tg mice 
Previous studies by our group showed that a short-term Af challenge protocol induces 
aggravated type 2 airway inflammation in juvenile Scnn1b-Tg mice (Fritzsching et al., 
2017). To evaluate the role of impaired MCC in the context of type 2 airway inflammation 
and to further determine the effects in an independent allergen model, we used a 
protocol consisting of intratracheal sensitization and challenge with the aeroallergen 
HDM. In detail, we sensitized and challenged 2- to 3-week-old juvenile WT and Scnn1b-
Tg mice with intratracheal application of the natural aeroallergen HDM or vehicle alone 
and compared inflammatory cell counts, levels of the type 2 cytokines IL-4, IL-5, and IL-
13 in BAL fluid, and AHR. In WT mice HDM induced a modest increase in BAL 
eosinophil counts, CD4+ T cells and IL-4, IL-5 and IL-13 levels (Figure 8A-E). In Scnn1b-
Tg mice BAL fluid eosinophil counts and IL-4, IL-5, and IL-13 levels were spontaneously 
increased, as described previously (Livraghi et al., 2009; Mall et al., 2008), and HDM 
triggered elevated levels of AMs, robust airway eosinophilia and production of IL-4, IL-5, 
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and IL-13 that was significantly increased compared with allergen-induced responses in 
WT mice (Figure 8A-E).  
 
 
Figure 8. HDM-exposure induces elevated type 2 airway inflammation in juvenile Scnn1b-Tg mice. 
(A-E) Juvenile WT and Scnn1b-Tg mice were sensitized and challenged with HDM or vehicle alone. (A) BAL 
cell counts (Airway macrophages [AM], eosinophils [Eos.], neutrophils [PMN], and lymphocytes [Lymph.]). 
(B) Airway CD4+ T cell counts. (C-E) IL-4 (C), IL-5 (D), and IL-13 (E) in BAL fluid. n = 13-23 mice for each 
group. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with vehicle-treated mice of the same genotype. 
†P < 0.05, ‡P < 0.01, and §P < 0.001 compared with mice with the same treatment but different genotype. 
Invasive pulmonary function testing demonstrated spontaneous AHR in naive juvenile 
Scnn1b-Tg versus WT mice (Figure 9) and HDM challenge increased AHR in juvenile 
WT and Scnn1b-Tg mice and was significantly aggravated in Scnn1b-Tg mice compared 
to WT littermates (Figure 9). In summary, these results demonstrate that impaired 
allergen clearance from the airways induces robust type 2 airway inflammation together 
with AHR in juvenile Scnn1b-Tg mice. 
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Figure 9. HDM-exposure exacerbates airway hyperresponsiveness in juvenile Scnn1b-Tg mice. 
Juvenile WT and Scnn1b-Tg mice were sensitized and challenged with HDM or vehicle alone and AHR was 
assessed by measuring respiratory resistance (Rrs). In HDM-exposed Scnn1b-Tg mice severe airway 
obstruction and mucus plugging of cannulae impeded ventilation, and measurements had to be discontinued 
at methacholine concentrations of greater than 32 mg/ml. n = 13-23 for each group. *P < 0.05, **P < 0.01, 
and ***P < 0.001 compared with vehicle-treated mice of the same genotype. †P < 0.05 and ‡P < 0.01 
compared with mice with the same treatment but different genotype. 
3.1.4 Allergen-induced type 2 airway inflammation and AHR are age-
dependent and correlate with type 2 signature genes in the mouse 
lung 
So far, our data demonstrated that juvenile Scnn1b-Tg mice with mucociliary dysfunction 
exhibit impaired allergen clearance that aggravates type 2 airway inflammation and AHR. 
Next, we were interested to determine the effects of impaired allergen clearance in adult 
mice. Therefore, we used our previously established short-term treatment protocol 
consisting of 4 Af challenges (Fritzsching et al., 2017), and exposed adult WT and 
Scnn1b-Tg mice to Af or vehicle alone and again compared inflammatory cell counts, 
IL-13 levels in BAL, and AHR. In comparison to vehicle-treated juvenile Scnn1b-Tg mice 
(Figure 8A and E), vehicle-treated adult Scnn1b-Tg mice did not show airway 
eosinophilia and increased IL-13 levels in BAL (Figure 10A and B) and consistent with 
previous studies airway inflammation was dominated by neutrophils (Figure 10A) (Gehrig 
et al., 2014; Mall et al., 2008). In adult WT and Scnn1b-Tg mice, Af-challenge neither 
induced type 2 airway inflammation nor AHR (Figure 10) and this is in contrast to 
previously published results in which Af-challenge triggered moderate type 2 airway 
inflammation in juvenile WT mice that was exacerbated in juvenile Scnn1b-Tg mice 
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(Fritzsching et al., 2017). These data suggest an age-dependent susceptibility to develop 
allergen-induced type 2 airway inflammation. 
 
 
Figure 10. Allergen-induced type 2 airway inflammation and airway hyperresponsiveness are age-
dependent. (A-C) Adult WT and Scnn1b-Tg mice were challenged with Af or vehicle alone and BAL 
inflammatory cell counts (Airway macrophages [AM], eosinophils [Eos.], neutrophils [PMN], and lymphocytes 
[Lymph.]) (A), IL-13 levels in BAL (B), and AHR by measuring respiratory resistance (Rrs) (C) were 
determined. n = 7-17 mice for each group). †P < 0.05 and ‡P < 0.01 compared with mice with the same 
treatment but different genotype. 
Previous studies indicated that the immune system in neonatal mice is biased towards a 
type 2 immunity (Adkins et al., 2004; Saglani et al., 2009) that could facilitate increased 
susceptibility to develop type 2 airway inflammation upon allergen exposure. To 
investigate the relationship between the age-dependent susceptibility to allergen 
challenge and reported skewing towards type 2 immunity in neonatal mice, we compared 
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expression levels of a set of type 2 signature genes including Il13, Muc5ac, Gob5, Arg1, 
Mmp12, Ym1, Ym2, and Chia (Lewis et al., 2009) in lung tissues from WT and Scnn1b-
Tg mice at neonatal, juvenile, and adult ages (Figure 11).  
 
 
Figure 11. Expression levels of type 2 signature genes are elevated in lungs of neonatal WT and 
Scnn1b-Tg mice. (A-H) Expression of the type 2 signature genes Il13 (A), Muc5ac (B), Gob5 (C), Arg1 (D), 
Mmp12 (E), Ym1 (F), Ym2 (G), and Chia (H) in naïve neonatal (10-day-old), juvenile (Juve.) (3-week-old), 
and adult (6-week-old) WT and Scnn1b-Tg mice. n = 7-16 mice for each group. *P < 0.05, **P < 0.01, and 
***P < 0.001 compared with mice with the same age but different genotype. †P < 0.05, ‡P < 0.01, and §P < 
0.001 compared with neonatal mice with the same genotype. #P < 0.05 and ¶P < 0.01 compared with 
juvenile mice with the same genotype. 
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Several type 2 signature genes (Il13, Muc5ac, Gob5, Arg1, and Ym2) in lungs of 
neonatal WT mice were significantly elevated compared with older WT mice (Figure 11). 
At all age groups, expression levels of investigated type 2 signature genes in Scnn1b-Tg 
mice were significantly increased compared to WT mice, however, these differences in 
expression waned for most of the signatures at adult ages (Figure 11). Taken together, 
these results confirm that the immune system in neonatal/juvenile mouse lungs is 
skewed towards a type 2 immunity and support that this bias is associated with the 
increased susceptibility to allergen-induced type 2 airway inflammation in juvenile WT 
mice, as well as exacerbated responses in juvenile Scnn1b-Tg mice with impaired 
allergen clearance. 
3.1.5 Pharmacological improvement of mucociliary clearance reduces 
allergen-induced type 2 airway inflammation and AHR in Scnn1b-Tg 
mice 
As a proof of concept, we were interested if improvement of MCC can reduce allergen-
induced type 2 airway inflammation. In previous studies, preventive treatment with the 
ENaC blocker amiloride improved airway surface hydration, MCC, and simultaneously 
decreases spontaneous type 2 airway inflammation in juvenile Scnn1b-Tg mice (Zhou et 
al., 2008). To investigate if improvement of airway surface hydration by ENaC inhibition 
has an effect on allergen-induced type 2 airway inflammation, we treated newborn WT 
and Scnn1b-Tg mice with airway instillations of amiloride or vehicle alone for 3 weeks 
and superimposed with an allergen provocation of Af or HDM in the presence of this 
treatment regime (Figure 12A and Figure 13A). Preventive amiloride treatment slightly 
reduced Af-induced airway eosinophilia (Figure 12C) but had no beneficial effects on 
HDM-induced type 2 airway inflammation including airway eosinophilia (Figure 13C), IL-
13 levels in BAL (Figure 13D), and AHR in WT mice (Figure 14A). In contrast to WT 
mice, preventive amiloride treatment significantly reduced exaggerated Af- and HDM- 
induced airway eosinophilia (Figure 12C and Figure 13C) and IL-13 levels in BAL (Figure 
12D and Figure 13D) in Scnn1b-Tg mice. Further, amiloride also prevented HDM-
induced AHR in Scnn1b-Tg mice (Figure 14B). In summary, these data demonstrate that 
pharmacological improvement of airway surface hydration protects juvenile Scnn1b-Tg 
mice from allergen-induced type 2 airway inflammation. 
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Figure 12. Pharmacological inhibition of ENaC reduces Af-induced type 2 airway inflammation in 
Scnn1b-Tg mice. (A-D) Newborn WT and Scnn1b-Tg mice were treated with airway instillation of amiloride 
or vehicle (ddH2O) alone from the first day of life for a period of 3 weeks. Challenge with Af or vehicle (NaCl 
0.9 %) alone was superimposed to amiloride treatment in juvenile mice (A), and BAL fluid total cell counts 
(B), eosinophil counts (C), and IL-13 levels (D) were determined. n = 14-49 in WT groups and n = 4-9 in 
Scnn1b-Tg groups. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with vehicle-treated (ddH2O and NaCl 
0.9 %) mice of the same genotype. †P < .05, ‡P < .01, and §P < .001 compared with vehicle-treated (H2O) 
Af-induced mice of same genotype. 
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Figure 13. Pharmacological inhibition of ENaC reduces HDM-induced type 2 airway inflammation in 
Scnn1b-Tg mice. (A-D) Newborn WT and Scnn1b-Tg mice were treated with airway instillation of amiloride 
or vehicle (ddH2O) alone from the first day of life for a period of 3 weeks. Sensitization and challenge with 
HDM or vehicle (NaCl 0.9 %) alone was superimposed to amiloride treatment in juvenile mice (A), and BAL 
fluid total cell counts (B), eosinophil counts (C), and IL-13 levels (D) were determined. n = 13-23 in WT 
groups and n = 16-28 in Scnn1b-Tg groups. **P < 0.01 and ***P < 0.001 compared with vehicle-treated 
(ddH2O and NaCl 0.9 %) mice of the same genotype. †P < 0.05 compared with vehicle-treated (H2O) HDM-
induced mice of same genotype. 
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Figure 14. Pharmacological inhibition of ENaC reduces HDM-induced airway hyperresponsiveness in 
Scnn1b-Tg mice. (A and B) Newborn WT and Scnn1b-Tg mice were treated with airway instillation of 
amiloride or vehicle (ddH2O) alone from the first day of life for a period of 3 weeks. Sensitization and 
challenge with HDM or vehicle (NaCl 0.9 %) alone was superimposed to amiloride treatment in juvenile mice 
and AHR by measuring respiratory resistance (Rrs) was determined in WT (A) and Scnn1b-Tg (B) mice. n = 
13-23 in WT groups and n = 16-28 in Scnn1b-Tg groups. *P < 0.05, **P < 0.01, and ***P < 0.001 compared 
with vehicle-treated (ddH2O and NaCl 0.9 %) mice of the same genotype. ‡P < 0.01 compared with vehicle-
treated (H2O) HDM-induced mice of same genotype. 
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3.2 Role of the adaptive immune system in chronic airway 
diseases 
Our study and previous published data demonstrated that the immune system in 
neonatal/juvenile mice is skewed towards a type 2 immunity (Adkins et al., 2004; Li et al., 
2004) and that the mucostatic environment in lungs of juvenile Scnn1b-Tg mice 
aggravates this bias (Fritzsching et al., 2017; Zhou-Suckow et al., 2017). Patients with 
CF lung disease suffer from a predominant neutrophilic airway inflammation (Conese et 
al., 2003) that is mostly triggered by signals from innate immune sources; however, there 
are also studies demonstrating that adaptive immunity including Th1-, Th2- and Th17- 
mediated inflammatory mechanisms contribute to chronic airway inflammation in lungs of 
CF patients.(Hartl et al., 2006; Hubeau et al., 2001; Tiringer et al., 2013). Further, it was 
shown that end-stage CF patients had an abnormal number of lymphoid follicles in their 
lungs that are rich in T and B cells (Lammertyn et al., 2017) and those were also found in 
Scnn1b-Tg mice with impaired MCC (Livraghi et al., 2009). Together these findings 
suggest a crucial role of the adaptive immune system contributing to these inflammatory 
processes. So far pathogenic mechanisms in CF lung disease that drive adaptive 
immune responses and their implications are only partially understood. To better 
understand these mechanisms in the development of CF lung diseases in vivo, we used 
Scnn1b-Tg mice as a model for CF-like lung disease and crossed them with Rag1-/- 
mice, that lack mature T and B cells (Mombaerts et al., 1992), and studied the lung 
phenotype of juvenile Scnn1b-Tg, double mutant Scnn1b-Tg/Rag1-/-, and WT and Rag1-/- 
littermates. 
3.2.1 T and B cells are not essential for chronic airway inflammation in 
juvenile Scnn1b-Tg mice 
To determine the role of T and B cells in the pathogenesis of chronic airway inflammation 
in mice with CF-like lung disease, BAL was performed and inflammatory cell counts were 
compared between juvenile WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. In line 
with previous studies (Mall et al., 2008), total inflammatory cells were significantly 
elevated in BAL fluid of juvenile Scnn1b-Tg mice compared to WT littermates (Figure 
15A). The lack of T and B cells had no effect on total inflammatory cells in Scnn1b-Tg 
mice (Figure 15A). The level of AMs was significantly increased in Scnn1b-Tg mice 
compared to WT controls (Figure 15B). In Scnn1b-Tg/Rag1-/- mice, AMs tended to be 
reduced compared to Scnn1b-Tg mice (Figure 15B), but, this difference did not reach 
statistical significance. BAL neutrophils and eosinophils were significantly increased in 
Scnn1b-Tg and Scnn1b-Tg/Rag1-/- mice compared to their WT and Rag1-/- littermates 
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and did not differ between Scnn1b-Tg and Scnn1b-Tg/Rag1-/- mice (Figure 15C and D). 
Collectively, these data indicate that chronic airway inflammation develops independently 
of the presence of T and B cells in juvenile Scnn1b-Tg mice. 
 
 
Figure 15. Chronic airway inflammation in juvenile Scnn1b-Tg mice develops independently of the 
presence of T and B cells. Total cell (A), airway macrophage (AM) (B), eosinophil (C), and neutrophil (D) 
counts in BAL fluid were determined by flow cytometry in juvenile WT, Rag1-/-, Scnn1b-Tg, and double-
mutant Scnn1b-Tg/Rag1-/- mice. n = 14-16 mice for each group. *P < 0.05, **P < 0.01 and ***P < 0.001 
compared with WT mice. 
3.2.2 Expression of Il17a is increased in the lungs of juvenile Scnn1b-Tg 
mice 
Studies in patients with CF demonstrated that i) Th1 cytokines, such as IFNγ ii) Th2 
cytokines, such as IL-4, IL-5 and IL-13, and iii) IL-17A and Th17-related cytokines, such 
as IL-6 and IL-8 are elevated in BAL fluid compared to healthy individuals (Tiringer et al., 
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2013). To investigate whether T and B cells are predominant sources and inducers of 
these cytokines in lungs of Scnn1b-Tg mice, we isolated RNA from lung tissue, 
performed real-time RT-PCR, and compared expression levels of Ifnγ, Il6, Cxcl1 (a 
functional mouse homolog for human Il8), Il4, Il5, Il13, and Il17a, between juvenile WT, 
Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice (Figure 16). 
 
 
Figure 16. Lack of T and B cells reduces Il17a expression in lungs of juvenile Scnn1b-Tg mice. (A-G) 
Gene expression of key Th1-, Th2-, and Th17-related cytokines in lungs of juvenile WT, Rag1-/-, Scnn1b-Tg, 
and Scnn1b-Tg/Rag1-/- mice. Expression levels of Ifnγ (A), Il6 (B), Cxcl1 (C), Il4 (D), Il5 (E), Il13 (F), and 
Il17a (G) were determined by real-time RT-PCR. n = 7-12 mice for each group. *P < 0.05, **P < 0.01 and 
***P < 0.001 compared with WT mice. §P < 0.001 compared with Scnn1b-Tg mice. 
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The expression level of Ifnγ was not different in lung tissues of juvenile WT, Rag1-/-, 
Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice (Figure 16A), but showed a trend to a 
somewhat decreased expression in lungs of Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. 
Th17-related genes Il6, Cxcl1 and Th2 signature genes Il4, Il5, and Il13 were elevated in 
Scnn1b-Tg mice compared to their WT and Rag1-/- littermates and deletion of Rag1 
showed no effect on the expression of these genes in Scnn1b-Tg mice (Figure 16B-F). 
Of note, gene expression of Il17a was significantly increased in lungs from Scnn1b-Tg 
mice compared to WT, Rag1-/-, and Scnn1b-Tg/Rag1-/- littermates (Figure 16G). Taken 
together, these data demonstrate a skewing towards a Th2- and Th17-associated 
cytokine profile in juvenile Scnn1b-Tg mice that correlates with findings previously 
observed in patients with CF lung disease (Tiringer et al., 2013) but also indicate that 
innate rather than adaptive immunity is a predominant source of these cytokines in vivo, 
with the exception of Il17a. 
3.2.3 The number of IL-17A-producing leukocytes is elevated in juvenile 
Scnn1b-Tg mice 
Because Il17a expression is increased in lungs of juvenile Scnn1b-Tg mice, and 
because different T cell populations are known to produce IL-17A, we next determined 
the cellular sources of IL-17A expression. According to the literature, CD4+ T, CD8+ T, 
γδ T and natural killer (NK)T cells are able to produce IL-17A. Besides T cells, NK cells 
and the recently discovered ILC3s are also capable of producing IL-17A (Cua and Tato, 
2010; Dubin and Kolls, 2011; Miossec and Kolls, 2012). Based on this information, we 
performed flow cytometry with intracellular staining against the cytokine IL-17A and 
developed a gating strategy (Figure 3) to identify these IL-17A producing cell types in the 
lungs of juvenile WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. We found that 
the percentage and total number of IL-17A positive leukocytes was significantly 
increased in Scnn1b-Tg mice compared to WT, Rag1-/-, Scnn1b-Tg/Rag1-/- littermates 
(Figure 17). Further, in Scnn1b-Tg/Rag1-/- mice the percentage and total number of IL-
17A+ leukocytes were elevated compared to Rag1-/- littermates (Figure 17) suggesting 
that T cells are not the only source for increased IL-17A secretion in Scnn1b-Tg mice. 
The number of lung-derived IL-17A-producing CD8+ T- and NKT cells did not differ 
between WT and Scnn1b-Tg mice (data not shown) nor did the number of lung-derived 
IL-17A-producing NK cells (data not shown). Interestingly, we detected significantly 
increased numbers of IL-17A+ CD4+ T and γδ T cells in lungs of Scnn1b-Tg mice 
compared to WT controls and in both groups the number of lung-derived IL-17A+ 
γδ T cells was about 6-fold higher than the number of IL-17A-producing CD4+ T cells 
(Figure 18A and B). The number of IL-17A+ ILC3s that are defined by the absence of 
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RAG-dependent rearranged antigen receptor, the lack of myeloid cell and dendritic cell 
phenotypical markers and expression of the transcription factor RORγt (Artis and Spits, 
2015; Spits et al., 2013), was significantly elevated in lungs of Scnn1b-Tg and Scnn1b-
Tg/Rag1-/- mice compared to WT and Rag1-/- controls (Figure 18C). This result indicates 
that besides T cells other cells, namely ILC3s, contribute to the augmented IL-17A 
secretion in juvenile Scnn1b-Tg mice. In summary, these data demonstrate an increased 
accumulation of IL-17A-producing, CD4+ T, γδ T cells, and ILC3s in lungs of juvenile 
Scnn1b-Tg mice and indicate that γδ T cells are the predominant source of IL-17A in 
both WT and Scnn1b-Tg mice. 
 
 
Figure 17. Increased number of IL-17A-producing leukocytes in lungs of juvenile Scnn1b-Tg mice. 
(A-C) Number of IL-17A expressing leukocytes that were isolated from lungs of juvenile WT, Rag1-/-, 
Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice and determined by flow cytometry after in vitro stimulation. (A) 
Representative dot plots of WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- leukocytes (CD45+). Number in 
rectangles represents percentage of IL-17A+ leukocytes. Percentage (B) and total number (C) of IL-17+ 
leukocytes in lungs of WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. n = 10-11 mice for each group. 
*P < 0.05 and ***P < 0.001 compared with WT mice. ¶P < 0.05 and #P < 0.001 compared with Rag1-/- mice. 
†P < 0.05 and ‡P < 0.01 compared with Scnn1b-Tg mice. 
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Figure 18. Augmented accumulation of IL-17A-producing CD4+ T, γδ T cells, and ILC3s in lungs of 
juvenile Scnn1b-Tg mice. (A-C) Single cells were isolated from lungs of mice, stimulated with PMA and 
ionomycin in vitro, and stained with the appropriate antibodies for the detection of intracellular IL-17A 
expression by flow cytometry. (A and B) The total number of lung-derived IL-17A+ CD4+ T (A) and IL-17A+ 
γδ T (B) cells isolated from juvenile WT and Scnn1b-Tg mice. Due to the fact that Rag1-/- and Scnn1b-
Tg/Rag1-/- mice lack T cells, they were not detected in those genotypes. (C) Total number of lung-derived IL-
17A+ ILC3s isolated from juvenile WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. n = 5-11 mice for 
each group. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with WT mice. 
3.2.4 Mucus obstruction develops independently of T and B cells in 
juvenile Scnn1b-Tg mice 
Previous studies demonstrated that juvenile Scnn1b-Tg mice suffer from severe mucus 
plugging which is a result of the combination of airway surface dehydration, impaired 
mucus clearance, and mucin overexpression that is driven by the chronic inflammatory 
milieu (Livraghi-Butrico et al., 2017). The understanding of the role of T and B cells in 
relation to impaired mucus clearance and mucus overproduction during chronic airway 
inflammation is limited (Cohn et al., 1997; Justice et al., 2002). Studies by Fujisawa et al. 
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showed that IL-17A could induce the expression of Muc5ac and Muc5b from airway 
epithelial cells ex vivo (Chen et al., 2003; Fujisawa et al., 2011; Fujisawa et al., 2009). 
Our results indicate that IL-17A production is increased in lungs of juvenile Scnn1b-Tg 
mice and that the lack of T cells, specifically γδ T cells, resulted in reduced Il17a 
expression (Figure 16 and Figure 18). Based on these findings, we investigated the 
effects of the depletion of T and B cells on airway mucus obstruction and mucin 
hypersecretion in juvenile Scnn1b-Tg mice in vivo. Therefore, we determined mucus 
obstruction by histological analysis, and expression of the mucins Muc5ac and Muc5b 
and the expression of the goblet cell marker gene Gob5 in lungs of juvenile WT, Rag1-/-, 
Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. 
 
 
Figure 19. Lack of T and B cells has no effect on mucus obstruction in juvenile Scnn1b-Tg mice. (A 
and B) Lung histology of AB-PAS stained sections from juvenile WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-
Tg/Rag1-/- mice. Lungs were sectioned at the level of the proximal main axial airway. (A) Morphology of AB-
PAS stained sections. Scale bars: 100 µm. (B) Summary of airway mucus content determined by the 
quantification of AB-PAS positive material in the airway lumen. n = 8-12 mice for each group. *P < 0.05 
compared with WT mice. 
The airways of WT and Rag1-/- mice were free of mucus, whereas obstructed airways 
were observed in Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice at similar levels (Figure 19A 
and B). In addition to airway mucus obstruction, Muc5ac and Muc5b expression were 
significantly increased to similar levels in Scnn1b-Tg and Scnn1b-Tg/Rag1-/- mice 
compared to WT and Rag1-/- mice (Figure 20A and B). The expression of the goblet cell 
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marker gene Gob5 was not changed between Scnn1b-Tg and Scnn1b-Tg/Rag1-/- mice 
but was elevated compared to their WT and Rag1-/- controls (Figure 20C). 
 
 
Figure 20. Mucin expression is independent of the presence of T and B cells in juvenile Scnn1b-Tg 
mice. Expression levels of Muc5ac (A), Muc5b (B), and Gob5 (C) were determined by real-time RT-PCR in 
juvenile WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. n = 7-8 mice for each group. *P < 0.05, **P < 
0.01 and ***P < 0.001 compared with WT mice. 
Collectively, these data indicate that T and B cells do not mediate mucus obstruction and 
mucin expression in lungs of juvenile Scnn1b-Tg mice although secretion of the mucus-
inducing cytokine IL-17A that is mainly produced by T cells is increased in juvenile 
Scnn1b-Tg mice. 
3.2.5 Lack of T and B cells reduces structural lung damage in juvenile 
Scnn1b-Tg mice 
Scnn1b-Tg mice develop structural lung damage which is mediated through increased 
protease activity associated with chronic inflammation (Fritzsching et al., 2015; Gehrig et 
al., 2014; Trojanek et al., 2014). Elevated secretion of IL-17A in the lung has also been 
associated with structural lung damage and emphysematous lesions in COPD (Kurimoto 
et al., 2013; Muir et al., 2016; Tan et al., 2011) and there is evidence that IL-17A can 
activate airway neutrophils through direct or indirect mechanisms leading to increased 
elastase activity on neutrophils that facilitates structural lung damage (Linden and 
Adachi, 2002). To determine if the lack of T and B cells affects structural lung damage in 
juvenile Scnn1b-Tg mice, mean linear intercepts and destructive index were compared 
between juvenile WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. 
Consistent with previous results (Trojanek et al., 2014), mean linear intercepts and 
destructive index were significantly increased in lungs of Scnn1b-Tg mice versus WT 
littermates (Figure 21). Interestingly, we found that the lack of T and B cells in 
Scnn1b-Tg mice significantly reduces structural lung damage, as shown by an 
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attenuation of mean linear intercepts and destructive index in Scnn1b-Tg/Rag1-/- mice 
(Figure 21). 
 
 
Figure 21. T and B cells contribute to structural lung damage in juvenile Scnn1b-Tg mice. (A-C) Lung 
histology of hematoxylin and eosin-stained sections from juvenile WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-
Tg/Rag1-/- mice. (A) Morphology of hematoxylin and eosin-stained sections. Scale bars: 100 µm. (B and C) 
Mean linear intercepts (B) were determined by the distances between alveolar walls, and destructive index 
(C) were determined by the percent of destructed alveoli. n = 6-12 mice for each group. *P < 0.05 compared 
with WT mice. †P < 0.05 compared with Scnn1b-Tg mice 
Taken together, the data demonstrate that the lack of T and B cells reduces distal 
airspace enlargement and alveolar wall destruction in juvenile Scnn1b-Tg mice and 
suggest that T cell mediated IL-17A secretion might be implicated in this process in CF-
like lung disease. 
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3.2.6 Lack of T and B cells attenuates airway macrophage activation in 
juvenile Scnn1b-Tg mice 
Previous studies demonstrated elevated activation of AMs that is associated with 
emphysema formation and structural lung damage in Scnn1b-Tg mice (Trojanek et al., 
2014). IL-17A could stimulate the recruitment and activation of AMs via direct or indirect 
mechanisms (Gaffen, 2008). To investigate the role of AM activation on reduced 
emphysema formation in Scnn1b-Tg/Rag1-/- mice, flow cytometry was performed and the 
population of AMs positive for the activation marker CD11b (Fritzsching et al., 2017) was 
determined in BAL of juvenile WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. 
 
 
Figure 22. T and B cells contribute to airway macrophage activation in juvenile Scnn1b-Tg mice.  
(A and B) BAL was performed and the percentage of CD11b+ airway macrophages (AMs) was determined 
by flow cytometry in juvenile WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. (A) Representative 
histogram plot of WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- AMs (Siglec-F+, CD11c+, MHCIImid, CD64+, 
F4/80+, and CD3-). Y-axis represents the percentage of the maximum count of AMs for each genotype. (B) 
Percentage of CD11b+ AMs in BAL of WT, Rag1-/-, Scnn1b-Tg, and Scnn1b-Tg/Rag1-/- mice. n = 15-17 mice 
for each group. ***P < 0.001 compared with WT mice. †P < 0.05 compared with Scnn1b-Tg mice. 
Consistent with previous studies (Fritzsching et al., 2017), we observed an increased 
activation of AMs in juvenile Scnn1b-Tg mice compared to WT littermates (Figure 22). In 
Scnn1b-Tg/Rag1-/- mice, AM activation was significantly reduced compared to Scnn1b-
Tg mice, but remained significantly elevated when compared to WT and Rag1-/- mice 
(Figure 22). These data indicate that T and B cells contribute to macrophage activation 
and that IL-17A may be implicated in this process. 
 
  Discussion 
  47 
4 Discussion 
The MCC apparatus is an important innate defense mechanism of the lung. It provides a 
highly effective defense against continuously inhaled noxious stimuli such as bacteria, 
viruses, allergens and other environmental irritants that are properly cleared from the 
airways by an intact MCC (Zhou-Suckow et al., 2017). Impaired MCC and/or excessive 
mucus secretion contribute to the pathogenesis of many chronic lung diseases including 
CF, asthma, and COPD (Fahy and Dickey, 2010). Chronic airway inflammation is a 
characteristic pathogenic feature of these lung diseases; however, mechanistic insights 
that unravel the relationship between impaired MCC and chronic airway inflammation 
and its functional consequences are limited. In this study, we focused on the role of MCC 
as an important innate defense mechanism in the pathogenesis of allergen-induced type 
2 airway inflammation and further investigated the role of T and B cells as key cells of 
the adaptive immunity in chronic airway diseases. 
4.1 Impaired mucociliary clearance triggers type 2 airway 
inflammation 
Previous studies demonstrated that asthma is associated with impaired MCC (Bateman 
et al., 1983; Messina et al., 1991) and the principal cause of death from asthma is 
asphyxiation from intraluminal airway obstruction caused by mucus plugs (Aikawa et al., 
1992; Messer et al., 1960). Type 2 airway inflammation including increased levels of 
eosinophils, type 2 signature cytokines, and AHR is a characteristic feature of allergen-
induced asthma (Lambrecht and Hammad, 2015). Type 2 inflammation not only 
contributes to disease severity in allergen-induced asthma but also in other chronic lung 
diseases with impaired MCC such as CF and COPD (Postma and Rabe, 2015; Tiringer 
et al., 2013). Many CF and COPD patients develop ABPA, a hypersensitivity against 
antigens of the fungi Aspergillus fumigatus, that is associated with increased type 2 
immune responses similar to those observed in allergen-induced asthma (Agarwal et al., 
2010; Jin et al., 2014; Knutsen and Slavin, 2011). However, underlying risk factors and 
mechanisms that trigger type 2 airway inflammation remain poorly understood. Based on 
these findings and reports we investigated the relationship between impaired MCC and 
allergen-induced type 2 airway inflammation. 
 
In this study, for the first time, we could link impaired MCC with reduced clearance of 
aeroallergens as a risk factor for the development of allergen-induced type 2 airway 
inflammation. By using a model that induces allergic asthma by intratracheal application 
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of the aeroallergen HDM, we showed that juvenile Scnn1b-Tg mice with reduced MCC 
develope an aggravated type 2 airway inflammation with airway eosinophilia, elevated 
levels of the type 2 signature cytokines IL-4, IL-5, and IL-13, and AHR (Figure 8 and 
Figure 9). These findings were further supported by previously published data from our 
group in which we used a short-term allergen challenge protocol consisting of 4 
intratracheal Af challenges in juvenile WT and Scnn1b-Tg mice (Fritzsching et al., 2017). 
This allergen-inducing asthma protocol triggered an aggravated type 2 airway 
inflammation together with GCM and AHR that was similar to that induced by the HDM 
sensitization and challenge protocol in juvenile Scnn1b-Tg mice (Figure 8 and Figure 9). 
Further, in this work, we demonstrated that transcript expression of Il33 and Il13 were 
strongly upregulated at baseline and after allergen challenge in airway epithelial cells of 
juvenile Scnn1b-Tg mice compared to WT littermates and that IL-33 could induce Il13 
expression in primary airway epithelial cells (Fritzsching et al., 2017). These findings 
showed a mechanism in which the airway epithelium is a considerable source for IL-13 
production and contributes to the orchestration of allergen-induced type 2 airway 
inflammation. Besides the induction of IL-13 from airway epithelial cells by IL-33, several 
other studies demonstrated that the release of IL-33 from the airway epithelium induces 
the production of IL-5 and IL-13 from ILC2s (Halim et al., 2012) and activation of AMs 
and Th2 cells (Kurowska-Stolarska et al., 2009; Louten et al., 2011) that were also 
identified to be one of the main IL-13 sources in juvenile Af-challenged Scnn1b-Tg mice 
(Fritzsching et al., 2017). A schematic overview of the relation between impaired MCC 
and the induction of allergen-induced type 2 airway inflammation is shown in Figure 23. 
 
AMs and cDCs are crucial cell types involved in asthma pathogenesis (Balhara and 
Gounni, 2012; van Rijt et al., 2005). Due to the fact that impaired MCC leads to reduced 
allergen clearance from the lungs and the airways of Scnn1b-Tg mice (Figure 4 and 
Figure 5), we were also interested whether the allergen uptake of AMs and cDCs is 
affected. We found a reduced allergen uptake by AMs in juvenile Scnn1b-Tg mice 
(Figure 6). In combination with impaired MCC, decreased allergen uptake by AMs might 
further contribute to impaired allergen clearance and thus to the overall burden of 
allergens in the lungs of Scnn1b-Tg mice. In contrast to the decreased allergen uptake 
by AMs, we found that the uptake by cDCs was significantly elevated in Scnn1b-Tg mice 
compared with WT littermates (Figure 7). This finding suggests that the enhanced 
allergen uptake by cDCs might be due to a more active phenotype of cDCs in the pro-
inflammatory milieu and/or an increased allergen load in mucostatic airways of Scnn1b-
Tg mice and thus might contribute to an elevated priming of effector T cells in Scnn1b-Tg 
mice (Figure 8B). 
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Figure 23. Schematic overview of impaired mucociliary clearance as a risk factor for the development 
of allergen-induced type 2 airway inflammation. (A) In healthy airways, the MCC apparatus functions 
normally and inhaled allergens and other environmental particles are properly cleared. (B) If MCC is 
impaired due to ASL dehydration and/or mucus hypersecretion, inhaled allergens are retained. This results 
in an activation of the airway epithelium and conventional dendritic cells (cDCs). The activated airway 
epithelium releases the cytokine IL-33 that leads to an autocrine activation as well as an activation and 
accumulation of Th2 cells and type 2 innate lymphoid cells (ILC2) and the secretion of IL-13 and other type 2 
cytokines driving key features of allergic airway inflammation including airway eosinophilia, goblet cell 
metaplasia (GCM) and mucus hypersecretion and airway hyperrespnsiveness (AHR). Figure is adapted from 
the publication by Fritzsching et al., 2017 and Zhou-Suckow et al., 2017. 
An interesting finding in our study was the age-dependent susceptibility of mice to 
develop allergen-induced type 2 airway inflammation in the context of impaired MCC. We 
found that a short-term allergen challenge protocol with Af neither induced type 2 airway 
inflammation nor AHR in adult WT and Scnn1b-Tg mice (Figure 10). In contrast, results 
from previous published work by our group showed that the same protocol induces 
airway eosinophilia, increased levels of type 2 signature cytokines in juvenile Af-
challenged WT mice that were exacerbated and associated with AHR in juvenile Af-
challenged Scnn1b-Tg mice (Fritzsching et al., 2017). We speculate that this age-
dependent susceptibility to develop allergen-induced type 2 airway inflammation 
originates from a type 2 biased immunity in the first weeks of life that makes the host 
susceptible to the development of allergen-induced type 2 airway inflammation. This 
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assumption is supported by several studies (de Kleer et al., 2016; Mall et al., 2008; 
Saglani et al., 2009; Steer et al., 2017). First, Saglani et al. observed that WT mice 
exposed to HDM from the first days of life developed an allergen-induced airway 
eosinophilia with elevated levels of type 2 cytokines that peaked at the juvenile age and 
waned at the adult age (Saglani et al., 2009). Second, Mall et al. observed that naïve WT 
and Scnn1b-Tg mice exhibit spontaneous increased eosinophil counts, IL-13 levels, and 
goblet cell counts in juvenile mice that were further enhanced in juvenile Scnn1b-Tg mice 
and waned in both genotypes at adult ages (Mall et al., 2008). Third, de Kleer et al. 
demonstrated that ILC2s, eosinophils, basophils, and mast cells spontaneously 
accumulate in juvenile WT mice in an IL-33-dependent manner and HDM exposure 
further increases levels of IL-33 that boost cytokine production in ILC2s and activates 
cDCs and thus facilitates enhanced neonatal/juvenile Th2 responses (de Kleer et al., 
2016). Fourth, a study similar to that from de Kleer et al., showed that elevated levels of 
IL-33 activates ILC2s in the neonatal/juvenile lung which then promote innate as well as 
adaptive type 2 immunity (Steer et al., 2017). 
The notion that juvenile mice are more susceptible to develop allergen-induced type 2 
airway inflammation than adults was further substantiated in our study by comprehensive 
analyses of a spectrum of type 2 signature genes, including Il13, Muc5ac, Gob5, Arg1, 
Mmp12, Ym1, Ym2, and Chia (Lewis et al., 2009) (Figure 11). We observed that the 
expression levels of most of the type 2 signature genes were upregulated in neonatal 
WT mice compared with older WT mice and this age-dependent type 2 pattern was 
exacerbated in Scnn1b-Tg mice (Figure 11). A similar type 2 biased immunity was 
observed in human subjects (Li et al., 2004; Prescott et al., 1998) and might explain why 
the onset of allergic asthma is observed especially in young children (Sennhauser et al., 
2005); however, future studies are needed to identify relationships between impaired 
MCC, allergen-induced type 2 airway inflammation, and age-dependent susceptibility in 
patients with allergic asthma. 
 
To test if pharmacological improvement of airway surface hydration and thus MMC might 
be an effective therapeutic target to reduce allergen-induced type 2 airway inflammation, 
we pretreated newborn WT and Scnn1b-Tg mice with the ENaC blocker amiloride and 
superimposed this treatment regime with Af or HDM challenges (Figure 12A and Figure 
13A). As mentioned before, ENaC is responsible for Na+ and fluid absorption from the 
airways (Knowles et al., 1981; Mall et al., 1998) and airway surface dehydration either 
because of ion imbalances between Cl- secretion and Na+ absorption or by mucus 
hypersecretion has been shown to be responsible for impaired MCC in many chronic 
lung diseases including asthma (Anagnostopoulou et al., 2012; Bonser et al., 2016; 
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Button et al., 2012; Evans et al., 2009). Amiloride and other hydration therapies have 
been applied in patients with CF and other chronic inflammatory lung diseases 
demonstrating an improvement of MCC (Daviskas et al., 1996; Houtmeyers et al., 1999; 
Kohler et al., 1986); however, the effects of this therapy on allergen-induced airway 
inflammation remain unknown. A previous study demonstrated that pharmacologic 
inhibition of ENaC from the first day of life reduced mucus obstruction and spontaneous 
type 2 airway inflammation in juvenile Scnn1b-Tg mice (Zhou et al., 2008). Therefore, 
the inhibition of ENaC is a pharmacological approach to improve airway surface 
hydration and MCC, and to test effects on allergic airway inflammation. Indeed, in our 
study amiloride treatment prevented exaggerated airway eosinophilia and IL-13 
production in Scnn1b-Tg mice and this finding was independent of the allergen that was 
applied (Figure 12 and Figure 13). Of note, preventive amiloride treatment also protected 
Scnn1b-Tg mice from allergen-induced AHR (Figure 14). The data from our study 
provides the first proof of concept that pharmacologic improvement of airway surface 
hydration and MCC in a susceptible host can reduce allergen-induced type 2 airway 
inflammation. Further, it shows that improvement of MCC might be an effective 
therapeutic approach to decrease or prevent chronic airway inflammation in patients with 
allergic asthma and other chronic airway diseases including CF and COPD that are 
associated with mucociliary dysfunction. 
4.2 Impaired mucociliary clearance and adaptive immunity 
Chronic airway inflammation is a pathogenic feature of many mucus-obstructed lung 
diseases (Barnes, 2008; Elizur et al., 2008). Specifically, in CF dehydrated mucus leads 
to impaired MCC and mucus plugging that drives chronic airway inflammation that is 
characterized by a neutrophil-dominated inflammation and bacterial/fungal infections 
(Elizur et al., 2008). Studies in Scnn1b-Tg mice mimicking the pathology of CF-like lung 
disease demonstrated that neutrophilic airway inflammation is triggered through 
epithelial necrosis due to mucus plug-induced hypoxia and the release of innate 
cytokines including IL-1α and IL-1β (Fritzsching et al., 2015), but also through increased 
activity of the protease neutrophil elastase and increased levels of the chemokine 
CXCL1 (Gehrig et al., 2014). All of these mechanisms were also connected to human CF 
patients. Also, bacterial and fungal infections activate pattern recognition receptors on 
airway epithelial and other innate immune cells leading to the release of pro-
inflammatory molecules including IL-1β, IL-6 and IL-8 that further boost neutrophilic 
airway inflammation in CF (Hartl et al., 2012). Much research has been done to unravel 
mechanisms that contribute to chronic airway inflammation in CF, mainly focusing on 
innate immune responses and its signal transducing molecules (Courtney et al., 2004; 
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Hartl et al., 2012; Laval et al., 2016). However, the effects of innate immune responses 
on adaptive immunity and its pathophysiological contribution in CF lung disease are 
poorly understood. Lately, efforts have been undertaken to investigate the contribution of 
the adaptive immune system to the chronic airway inflammation (Ratner and Mueller, 
2012), thereby showing that mechanisms triggered by Th2 and Th17 immunity might be 
implicated in chronic airway inflammation in CF (Hubeau et al., 2004; Tan et al., 2011; 
Tiringer et al., 2013). Another study showed that the function of regulatory T cells is 
impaired in CF patients chronically infected with Pseudomonas aeruginosa (Hector et al., 
2015). Further, lymphoid follicles that are rich in T and B cells were found in patients with 
end-stage CF lung disease (Lammertyn et al., 2017). Based on these results and 
reports, we investigated the role of the adaptive immune system in the development of 
chronic airway inflammation in Scnn1b-Tg mice. Therefore, we crossed Rag1-/- mice with 
Scnn1b-Tg mice and studied the lung phenotype of Scnn1b-Tg mice that lack mature T 
and B cells. We investigated the pulmonary phenotype at the juvenile age because at 
this period we expected the most prominent changes concerning Th2-related 
mechanisms when T and B cells are lacking. This assumption was based on the facts 
that juvenile mice have a type 2 biased immune system as we have shown before 
(Figure 11) and that Scnn1b-Tg mice at this age develop a spontaneous type 2 airway 
inflammation in addition to airway neutrophilia (Mall et al., 2008). 
 
We found that the development of chronic airway inflammation was not mediated by T 
and B cells in juvenile Scnn1b-Tg mice as the inflammatory cells including AMs, 
eosinophils, and neutrophils in BAL did not change between Scnn1b-Tg and Scnn1b-
Tg/Rag1-/- mice (Figure 15). Elevated levels of IL-5 and IL-13 are strong indicators for 
eosinophilic airway inflammation (Pope et al., 2001) whereas increased levels of IL-6 
and CXCL1 correlate with neutrophilic airway inflammation (Fielding et al., 2008; 
Hammond et al., 1995). Transcript expression of these molecules was increased in 
Scnn1b-Tg and Scnn1b-Tg/Rag1-/- mice compared to WT and Rag1-/- littermates and 
associated with elevated levels of airway eosinophils and neutrophils in Scnn1b-Tg and 
Scnn1b-Tg/Rag1-/- mice (Figure 15 and Figure 16). These findings demonstrate that 
chronic airway inflammation is largely driven by innate inflammatory mechanisms in 
juvenile Scnn1b-Tg mice including the production of IL-5 and IL-13 by ILC2s and the 
airway epithelium (Fritzsching et al., 2017; Halim et al., 2012) and IL-6 and CXCL1 by 
AMs and the airway epithelium (Kotloff et al., 1990; Marini et al., 1992; Mukaida, 2003). 
 
As mentioned above, previous studies demonstrated a Th2- and Th17-skewed cytokine 
profile in patients with CF (Tiringer et al., 2013). In our study, we were interested if there 
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is such a Th2- and Th17-skewed cytokine profile in juvenile Scnn1b-Tg mice that 
correlates with that found in CF patients and whether these cytokines are predominantly 
expressed by innate or adaptive immune cells. To address these questions, we 
measured transcript expression levels of Th1- (Ifnγ), Th2- (Il4, Il5, and Il13) and Th17-
related (Il6, Cxcl1, and Il17a) cytokines in lung homogenates of juvenile WT, Rag1-/-, 
Scnn1b-Tg and Scnn1b-Tg/Rag1-/- mice (Figure 16). Nearly all of the cytokines including 
Il4, Il5, Il13, Il6, Cxcl1, and Il17a were upregulated in Scnn1b-Tg mice (Figure 16B-G) 
and this correlates with findings in CF patients (Tiringer et al., 2013). The transcript 
expression of most cytokines including Ifnγ, Il4, Il5, Il13, Il6, and Cxcl1 was not changed 
between Scnn1b-Tg and Scnn1b-Tg/Rag1-/- mice (Figure 16A-F) demonstrating that the 
expression of these cytokines is mediated by innate rather than by adaptive mechanisms 
including T and B cells. 
An interesting finding was that the transcript expression of Il17a, a cytokine that is 
associated with activation and migration of neutrophils, bacterial defense and structural 
lung damage, was upregulated in juvenile Scnn1b-Tg mice compared to WT and Rag1-/- 
littermates and was significantly downregulated to levels of WT mice when T and B cells 
were lacking as seen for Scnn1b-Tg/Rag1-/- mice (Figure 16G). This result indicates that 
IL-17A is a major source of T and/or B cells in juvenile Scnn1b-Tg mice and correlates 
with previous findings in CF patients showing increased levels of IL-17A (Tan et al., 
2011; Tiringer et al., 2013). 
 
According to the literature, T cells rather than B cells are able to produce IL-17A. CD4+ T, 
CD8+ T, γδ T and NKT cells are subclasses of T cells that have been shown to produce 
IL-17A and besides T cells, innate cells including NK cells and the recently discovered 
ILC3s are also capable of producing IL-17A (Cua and Tato, 2010; Dubin and Kolls, 2011; 
Miossec and Kolls, 2012). In our study, we identified significantly elevated numbers of IL-
17A-producing leukocytes in lungs of juvenile Scnn1b-Tg mice (Figure 17). Specifically, 
increased levels of IL-17A-expressing CD4+ T and γδ T cells were identified in Scnn1b-
Tg mice (Figure 18A and B) and this is in line with previous findings in CF patients (Chan 
et al., 2013; Tan et al., 2011). An interesting finding was that the number of IL-17A+ 
ILC3s was increased in Scnn1b-Tg mice and Scnn1b-Tg/Rag1-/- mice compared to WT 
and Rag1-/- littermates and did not differ between Scnn1b-Tg and Scnn1b-Tg/Rag1-/- 
mice (Figure 18C). These results suggest that besides T cells, ILC3s might be a 
considerable source of elevated IL-17A expression in CF lung disease. Further, we 
noted that the number of IL-17A-producing γδ T cells derived from WT and Scnn1b-Tg 
mice was about 4 to 6-fold higher than the number of IL-17A+ CD4+ T cells and ILC3s 
indicating that γδ T cells are a predominant source of IL-17A and might contribute to 
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pathogenic features of CF lung disease (Papotto et al., 2017; Tan et al., 2011). In 
summary, our data demonstrate increased numbers of IL-17A-producing CD4+ T, γδ T 
cells and ILC3s in lungs of juvenile Scnn1b-Tg mice and indicate that IL-17A might be an 
important player in CF lung disease. Further studies are needed to investigate IL-17A 
signaling and its impact on pathogenic features in CF lung disease. 
 
Besides other mucus-inducing molecules including IL-1β, IL-6, IL-13, and neutrophil 
elastase (Chen et al., 2003; Fritzsching et al., 2015; Gehrig et al., 2014; Zhu et al., 
1999), IL-17A is also known for its mucus-inducing function (Chen et al., 2003; Fujisawa 
et al., 2011; Fujisawa et al., 2009). Previous studies demonstrated that Scnn1b-Tg mice 
suffer from airway mucus plugging that is caused by airway surface dehydration, 
impaired MCC and mucus hypersecretion (Mall et al., 2008). However, mucus plugging 
could also occur in the absence of mucus hypersecretion in Scnn1b-Tg mice (Gehrig et 
al., 2014), thus indicating that mucus hypersecretion alone is not always associated with 
mucus obstruction under conditions of well hydrated airway surfaces (Button and Button, 
2013). We hypothesized that the removal of T cells via Rag1-deficiency and the 
associated loss of a major source of IL-17A, might lead to reduced mucus secretion and 
plugging in Scnn1b-Tg mice. Our results showed that the lack of T cells did not affect 
mucus plugging (Figure 19A and B) or mucin hypersecretion of the two mucins Muc5ac 
(Figure 20A) and Muc5b (Figure 20B) in juvenile Scnn1b-Tg mice. Further, we detected 
similar elevated expression levels of the goblet cell marker Gob5 in Scnn1b-Tg and 
Scnn1b-Tg/Rag1-/- mice (Figure 20C). These results suggest that either elevated 
secretion of IL-17A by ILC3s still maintains mucus hypersecretion and plugging in 
juvenile Scnn1b-Tg/Rag1-/- mice or, which is more likely, that other mucus-inducing 
molecules including IL-1β, IL-13 and neutrophil elastase are more potent than IL-17A to 
induce mucus hypersecretion and plugging in juvenile Scnn1b-Tg mice (Fritzsching et 
al., 2015; Gehrig et al., 2014; Zhu et al., 1999).  
Collectively, these results demonstrate that T cell mediated IL-17A expression rather 
plays a minor role in the context of mucin hypersecretion and mucus plugging, in 
comparison to IL-1β, IL-13 and neutrophil elastase in juvenile Scnn1b-Tg mice and thus 
maybe also in patients with CF lung disease. 
 
Previous studies demonstrated that IL-17A is involved in structural lung damage and 
emphysema formation (Kurimoto et al., 2013; Muir et al., 2016) and B cell-mediated 
emphysema formation was demonstrated in mice with cigarette smoke-induced COPD 
(van der Strate et al., 2006). Scnn1b-Tg mice develop structural lung damage and 
emphysema that was linked to elevated protease activity (Gehrig et al., 2014; Mall et al., 
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2008; Trojanek et al., 2014). By the lack of T and B cells due to Rag1 deficiency, we 
speculated that structural lung damage and emphysema formation might be reduced in 
Scnn1b-Tg mice. Indeed, we observed a reduction of destructive index, a measure for 
alveolar wall destruction, and mean linear intercept, a measure for alveolar airspace 
enlargement, in Scnn1b-Tg/Rag1-/- mice compared to Scnn1b-Tg mice (Figure 21). We 
speculate that the reduction in structural lung damage is linked to the absence of T cell-
produced IL-17A rather than the lack of B cell-mediated mechanisms in Scnn1b-
Tg/Rag1-/- mice because a study by John-Schuster et al. demonstrated that elastase-
induced emphysema still develops in B cell-deficient mice and was as severe as in WT 
mice (John-Schuster et al., 2014). Several mechanisms might contribute to IL-17A-
induced structural lung damage in Scnn1b-Tg mice. First, IL-17A could induce neutrophil 
recruitment to the lung and might also enhance neutrophil activation by increasing 
elastase activity (Linden and Adachi, 2002). In our study, we did not observe a reduction 
in neutrophil counts in the BAL of Scnn1b-Tg/Rag1-/- mice (Figure 15D) and this 
suggests that other mechanisms including elevated levels of the neutrophil attractants 
IL-6 (Figure 16B) and CXCL1 (Figure 16C) might compensate the effects of potentially 
decreased IL-17A-induced neutrophil recruitment in Scnn1b-Tg/Rag1-/- mice. Thus, these 
findings argue that neutrophil activation rather than recruitment might play a role in IL-
17A-induced structural lung damage in Scnn1b-Tg mice. Second, IL-17A could also 
recruit macrophages to the lung via direct or indirect mechanisms (Bozinovski et al., 
2015; Gaffen, 2008; Voss et al., 2015) and has the potential to stimulate the release of 
matrix metalloproteinases from AMs that contribute to structural lung damage and 
emphysema formation (Gaffen, 2008; Jovanovic et al., 2000; Prause et al., 2004; 
Trojanek et al., 2014). In our study, we observed a trend towards a reduced level of AMs 
in BAL of Scnn1b-Tg/Rag1-/- mice compared to Scnn1b-Tg mice (Figure 15A). Further, 
we measured activation of AMs through the expression of CD11b that might mediate 
inflammation by regulating leukocyte adhesion and migration (Solovjov et al., 2005). We 
observed a reduced AM activation phenotype in Scnn1b-Tg/Rag1-/- mice compared to 
Scnn1b-Tg mice (Figure 22). 
Collectively, these findings indicate that reduced structural lung damage and 
emphysema formation in juvenile Scnn1b-Tg/Rag1-/- mice might be associated with the 
lack of T cell mediated IL-17A expression; however, further studies are required to 
elucidate IL-17A-dependent mechanisms triggering structural lung damage in CF-like 
chronic airway inflammation. 
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5 Conclusions 
Patients with mucus-obstructed lung diseases including CF, asthma and COPD develop 
chronic airway inflammation that differ in their immune responses. The understanding of 
mechanisms and risk factors that lead to chronic airway inflammation and their 
pathophysiological contributions in muco-obstructive lung diseases is crucial to allow the 
design of effective treatment strategies. In this work, we investigated the role of MCC as 
an important innate defense mechanism in the pathogenesis of allergic airway disease 
and also aimed to understand the role of T and B cells as key cells of the adaptive 
immunity in chronic airway diseases in context of CF-like lung disease. 
For the first time, this study demonstrates that mucociliary dysfunction causing reduced 
clearance of inhaled allergens from the airways represents an important risk factor for 
the development of allergen-induced type 2 airway inflammation. Further, our results 
demonstrated that allergen-induced airway inflammation is related to an age-dependent 
susceptibility that is most likely caused by a type 2 biased immune system in early life. 
Finally, we showed that pharmacological improvement of airway surface hydration and 
MCC reduces allergen-induced type 2 airway inflammation and AHR in a susceptible 
host. 
Analyzing the lung phenotype of juvenile Scnn1b-Tg/Rag1-/- mice gave first insights into 
the pathophysiological contribution of the adaptive immune system and its interaction 
between innate immunity in CF-like lung disease. Our data showed that chronic airway 
inflammation is rather mediated by innate than adaptive immune responses in Scnn1b-
Tg mice. We found that many of the cytokines orchestrating chronic airway inflammation 
in CF are produced by innate cellular sources in juvenile Scnn1b-Tg mice and confirmed 
a Th2- and Th17-skewed cytokine profile previously found in CF patients (Tiringer et al., 
2013). The identification of increased levels of IL-17A predominantly produced by 
CD4+ T, γδ T cells and ILC3s in lungs of Scnn1b-Tg mice showed no effect on mucus 
plugging but seem to be implicated in the development of structural lung damage. 
In summary, our data support that impaired clearance of inhaled allergens plays an 
important role in the pathogenesis of type 2 airway inflammation and suggest that 
therapeutic improvement of MCC may be an effective novel therapeutic target in patients 
with allergen-induced asthma and potentially other chronic airway diseases associated 
with mucociliary dysfunction including CF and COPD. Further, results from our study 
provided first insights into T and B cell-dependent mechanisms that might contribute to 
pathophysiological features of CF lung disease. 
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6 Future Perspectives 
We identified impaired MCC with reduced allergen clearance as a risk factor for the 
development of type 2 airway inflammation. Reduced uptake of allergens by AMs 
contributed to the increased burden of allergens in the airways of juvenile Scnn1b-Tg 
mice. Mechanisms of reduced allergen uptake by AMs were not investigated in this study 
as this was beyond the scope of this project; however, the identification of such 
mechanisms could lead to a better understanding of the development of allergen-
induced type 2 airway inflammation. Conversely, we observed elevated allergen uptake 
by cDCs that suggested an enhanced allergen presentation to T cells and a further boost 
of type 2 airway inflammation. This assumption could be addressed by in vitro co-culture 
experiments of allergen primed cDCs and T cells from juvenile WT and Scnn1b-Tg mice. 
The observation that allergen-induced type 2 airway inflammation is mediated by an age-
dependent susceptibility that is likely due to a type 2 biased immunity at 
neonatal/juvenile age is an interesting result. Some genes of the type 2 signature pattern 
including Muc5ac and Gob5 that were elevated at neonatal/juvenile age are exclusively 
derived from airway epithelial cells supporting an important role of the airway epithelium 
in the age-dependent susceptibility. Transcriptomic and proteomic analyses of airway 
epithelial cells from neonatal, juvenile and adult WT and Scnn1b-Tg mice might lead to 
further important insights concerning this issue. Pharmacological improvement of airway 
surface hydration and MCC reduced allergen-induced type 2 airway inflammation and 
AHR demonstrating that improving MCC might be a potential therapeutic strategy in 
patients with allergen-induced asthma. Effects of other ENaC blockers targeting MCC 
should be tested in vivo in context of allergen-induced type 2 airway inflammation. Also, 
the effects of reducing agents breaking disulfide bonds of mucus polymers should be 
tested. These drugs thin mucus making it less sticky and easier to clear thereby having a 
potential therapeutic effect on MCC and allergen-induced type 2 airway inflammation that 
might be similar to that of hydration therapies with ENaC blockers. 
By the investigation of the pathogenic contribution of the adaptive immunity in Scnn1b-
Tg mice, we found that the lack of T and B cells is associated with reduced structural 
lung damage and that IL-17A may be implicated in this process. To determine the role of 
IL-17A in more detail in vivo, IL-17A-knockout mice should be crossed with Scnn1b-Tg 
mice. The confirmation of our current observations and findings of new pathogenic 
IL-17A-dependent mechanisms in these mice might give new insights into the complex 
network of chronic airway inflammation in CF lung disease. In addition, translational 
studies to confirm the significance of our findings in patient tissues are still needed. 
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